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A. Abstract 
Pseudomonas aeruginosa is the fourth most commonly isolated hospital pathogen, multidrug 
resistant and potentially deadly causes of pneumonia. Patients at risk of acquiring P. aeruginosa are 
immunocompromised , due to immunosuppressive therapies or underlying diseases such as cancer, 
AIDS or the hereditary disease cystic fibrosis (CF). P. aeruginosa-host interaction is driven by 
several factors including the bacterial phenotype and the host genetic make- up.  
From the bacterial side, several virulence factors have been attributed to P. aeruginosa 
pathogenicity while many others remain to be established. One third of the P. aeruginosa genome 
has no attributed homology to any previously reported sequences with only 6.7% of its genes 
having a function verified experimentally. To identify novel virulence genes, a genome-wide multi-
host in vitro and in vivo screening was carried out. A library of 57,360 P. aeruginosa Tn-5 mutants 
was screened for phenotypic virulence traits (e.g. swarming, pyocyanin, and protease). A total of 
404 Tn5-mutants showing pleiotropic phenotypes were tested in the C. elegans and D. 
melanogaster infection models and further reduced for validation in cell culture and animal models. 
In particular, 28 selected Tn5-mutants were tested for invasion and IL-8 production in immortalized 
respiratory A549 cells. Mortality, inflammation and lung pathology  of eight selected mutants were 
scored in C57BL/6 mice and five out of eight mutants were significantly attenuated in inducing 
murine mortality. The Tn5 gene insertion sites were mapped and their conservation established 
across seven P. aeruginosa genomes by comparative sequence analysis. The Tn-5 inserted genes 
encoded proteins from several functional classes including hypothethical, catabolism regulation, 
iron uptake and quorum sensing. This screening generated a list of virulence-related genes relevant 
for pathogenicity in multi-hosts and favour much needed insight into the aspects of P. 
aeruginosa/host interaction. 
From the host side, the clinical outcome of P. aeruginosa infections may be extremely variable 
among individuals at risk including CF patients. However, risk factors for P. aeruginosa infection 
remain largely unknown. To characterize how the genetic background influences P. aeruginosa 
lung infections, nine different inbred mouse strains were infected with P. aeruginosa clinical isolate 
and monitored for body weight change and mortality up to seven days. Next, one of the most 
susceptible and resistant mouse strains were further characterized by scoring  bacterial count, cell-
mediated immunity, cytokines and chemokines profile and lung pathology in an early time course. 
Susceptible mice showed a significantly higher bacterial burden, higher cytokines and chemokines 
levels but lower leukocyte recruitment, and a lower inflammatory severity damage when compared 
to resistant ones. Our results indicated that host genetic make-up may have a role in the modulation 
of cell-mediated immunity playing a critical role in the control of P. aeruginosa infection.  
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B. State of the Art 
B.1 Pseudomonas aeruginosa respiratory infections: epidemiology and 
pathogenesis   
Pseudomonas aeruginosa is an aerobic Gram negative bacterium  found in several waterborne 
environments throughout nature [1]. It has a large genome containing a myriad of pathogenic and 
metabolic capabilities allowing it to infect many different organisms, including plants, amoebas, 
nematodes and vertebrate animals [2]. Given its ubiquitous presence in the environment and 
pathogenic potential, this microorganism is an important cause of both community-acquired 
infections (e.g. keratitis, otitis externa, skin and soft tissue infections) and hospital-acquired ones 
(e.g. pneumonias, urinary tract infections, surgical site and skin infections in the setting of burn 
injuries). Considering respiratory infection, P. aeruginosa can cause community acquired 
pneumonia (CAP) with high rate of incidence in nursing home resident, patients with chronic 
obstructive pulmonary disease (COPD) and patients recently discharged from the hospital. It has 
also been identified as the second most common cause of hospital-acquired pneumonia (HAP) and 
ventilator-associated pneumonia (VAP), with mortality rates of 34 to 48 %, exceeded in frequency 
only by Staphilococcus aureus [3]. In intensive care units (ICUs), P. aeruginosa is typically 
responsible for an even higher percentage of nosocomial infections, with rates of 13.2-22.6 % 
reported [4] [5] [6, 7]. 
P. aeruginosa rarely causes infections in immune-competent patients in which the acquisition of 
environmental bacterial cells is normally resolved by the immune system. However, P. aeruginosa 
may cause infection when normal cutaneous or mucosal barriers are broken (e.g trauma, surgery, 
serious burns or indwelling devices), when disruption of the protective balance of normal mucosal 
flora by broad spectrum antibiotic occurs, or in patients with a deficiency in the immune response 
caused by immunosuppressive therapies or viral infections. In particular patients at high risk of lung 
infections caused by P. aeruginosa are immunocompromised like transplant recipients, neutropenic 
patients and patients with HIV. In one study of patients infected with HIV, the incidence of P. 
aeruginosa bacteremia was approximately 10 times the rate of that seen in the general population of 
the participating hospitals, and in this category of patients P. aeruginosa was identified as the most 
common cause of bacterial bronchopneumonia [7]. Solid organ transplant and bone marrow 
transplant patients have increased rates of P. aeruginosa bacteremia, in the specific case of lung 
transplant the pathogen becomes an important cause of late-onset pneumonia [8].  
Patients with cystic fibrosis (CF), the most frequent lethal genetic disease in Caucasian population, 
are particularly susceptible to P. aeruginosa. One of the physiological consequences of a defective 
CF Transmembrane Conductance Regulator (CFTR) protein in the airway epithelium is the 
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production of a thick and viscous mucus that creates special niches for P. aeruginosa colonization, 
leading to chronic persistence. In particular, mutations in the cftr gene cause a critical impairment 
of innate host defence systems in the lungs that results in an early and severe form of chronic 
airway disease featuring mucus obstruction, neutrophil dominated airway inflammation and 
bacterial infection, finally leading to progressive pulmonary damage with bronchiectasis and 
emphysema[9] [10] [11]. Early respiratory insufficiency due to chronic airway inflammation with 
recurrent P. aeruginosa infection is considered the major cause of morbidity and mortality in CF 
patients. About 80 % of adult CF patients suffer from chronic P. aeruginosa lung infections which 
are responsible for their short life expectancy with a median predicted survival of 37.8 years (Fig.1) 
[12]. 
 




B.2 Pathogenesis of cystic fibrosis lung disease 
B.2.1 Epidemiology of CF: CFTR structure, function and mutations 
CF, cause by mutations in the cftr gene, is the most common life shortening, autosomal, recessive 
monogenic disease which affects approximately 30.000 individuals in the United States and about 
70.000 worldwide.  
The 230 kb cftr gene, with 27 exons located at the long arm of chromosome 7 (7q31.3), encodes a 
c-AMP responsive chloride channel in lipid bilayers of the apical membrane of epithelial cells 
lining the respiratory and digestive tracts. The CFTR is the only known member of the ABC family 
that acts as an ion channel [13, 14]. The mature 1480-residue long membrane protein is composed 
by two transmembrane domains, two nucleotide domains, an additional regulatory region, as well as 
N- and C-terminal extensions of about 80 and 30 residues in length, respectively. Each membrane-
spanning domain contains six membrane-spanning alpha helixes portions forming a chloride-
conductance pore. Channel activity is governed by the two nucleotide binding domains and the 
Figure 1: Median predicted survival age in CF patients. Rise in median predicted survival age since 1988 in 5-year bands or groups. For 2008-2012, the 
median predicted survival was 37.8 years.[12]. 
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regulatory domain, while the C-terminal domain, that is anchored to the cytoskeleton, interacts with 
other proteins that influence CFTR function (Fig.2).  
 




Although CFTR is primarily a chloride channel, it also control the transport of other ions and 
molecules as well as the function of several membrane channels, such as the epithelial sodium 
channel (ENaC), potassium channels and outwardly rectifying chloride channel [15-17]. 
Consequently CFTR regulates the hydration of the airways’ surface fluid. 
To date, there are more than 1900 different mutations in the cftr gene that are known to cause CF, 
but over than 90 % of cases are associated with a recessive deletion mutation of phenylalanine at 
position 508 (∆F 508) [18]. CFTR mutations are classified into 5 groups: Class 1 mutations cause a 
defect in CFTR protein synthesis , such as the premature stop codon W128X; Class 2 mutations, 
including the first most common ∆F508, are translated into full length nascent polypeptide chains, 
but are defective in folding and targeted for degradation rather than trafficked to plasma membrane; 
Class 3 CFTR mutants are able to reach the plasma membrane but have channel gating defects that 
decrease channel opening time and decrease chloride flux, e.g the second most common mutation 
G551D; Class 4 mutants reach the plasma membrane but have decreased channel conductance even 
when the gate is open; and Class 5 mutants show a fully functional CFTR at the level of plasma 
membrane with reduced abundance due to defective mRNA splicing. Each of these classes of 
mutations cause a multi organ disorder in which the level of functional CFTR is important in 
determining the severity of disease.  
 
 
Figure 2: CF transmembrane conductance regulator (cftr) gene and its encoded polypeptide 
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B.2.2. Impact of defective CFTR on airway physiology and mucociliary clearance 




 thereby helping to regulate the airway surface liquid 
(ASL) volume and composition also by interacting with other channel such as the ENaC. In the 
respiratory tract, ASL, including the periciliary liquid layer (PCL) and the mucus layer, is a first 
line of defence against inhaled or aspirated pathogens providing a barrier between the epithelium 
and inspired air and its regulation reflects the balance between Na
+
 absorption and Cl
- 
secretion 
mediated by EnaC and CFTR channels respectively. The PCL covers the cilia, hydrating mucins 
and allowing for ciliary beating by distancing the mucus from the cell surface. The mucus layer is 
comprised of secreted and tethered mucins produced by surface goblet cells and submucosal gland 
epithelia (Fig.3).  





In a normal epithelium the presence of an hydrated and low viscous PCL promotes an efficient 
mucocilliary clearance of pathogen trapped in the mucus layer. A normal rate of epithelial cells 
oxygen consumption results in homogenous pressure of oxygen (pO2) within the ASL (Fig.4a). On 
the contrary in CF airways, the absence of a functional CFTR induces a hyper absorption of Na
+
 
and water across the epithelia. This phenomenon generates a volume depletion of the PCL, resulting 
in reduced mucocilliary clearance (Fig.4b). A persistent mucus hypersecretion by secretory 
gland/goblet cells increases the height of the luminal mucus layer/plugs (Fig.4c). In addition the 
accelerated Na
+
 absorption is fuelled by an increased turnover rate of ATP- consuming Na-K- 
ATPase pumps leading to two-to threefold increases in CF airway epithelial O2 consumption, 
contributing to create a stepper O2 gradient in the ASL. 
Moreover an impaired HCO3
-
 secretion leads to a decrease of ASL pH. Of note, mucins become 
more viscous at acidic pH and this may contribute to the thick hypoxic mucus plaque formation that 
characterize CF airways as an expression of the persistent and uncontrolled hyper secretory activity 
Figure 3: A simplified model of the airway epithelium. The airway epithelium has two compartments, the surface epithelium and the submucosal gland (SMG) 
epithelium. The airway surface  epithelium includes ciliated and non-ciliated cells, goblet cells. SMG epithelium includes ciliated duct cells, mucus cells and 
serous cells that secret antimicrobial proteins. Airways surface liquid (ASL) is composed of two layers a mucus gel layer and a periciliary layer. 
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of mucus gland. It was also well described that changes in pH of CF ASL negatively impact on the 
activity of many antimicrobials. The cathelicidin LL37, for example, undergoes a conformation 
change that decreases its antibacterial activity [19]. An acidic environment also reduces the amount 
of human β defensin1 produced by airway epithelial cells [20].The pH sensitivity of numerous 
airway antimicrobials is a probable causal link between reduced ASL pH in CF and the impaired 
antibacterial activity of CF ASL, and consequent bacterial infections. 
The hypoxic gradient in the thickened mucus layer creates a favourable environment for the 
opportunistic P. aeruginosa, able to penetrate actively and/or passively due to mucus turbulence 
into hypoxic zones within mucus masses. In these conditions the bacterium adapts to hypoxic 
niches with increased alginate production and macro colonies creation (Fig.4d,e). These macro-
colonies are resistant to secondary defences including neutrophils and antibiotic treatment (Fig.4f). 
All above-mentioned pathogenic events favour the persistence of P. aeruginosa, setting the stage 














B.2.3 Microbiology of CF lung disease  
Traditional aerobic culture-based studies of spontaneous expectorated sputa indicate that CF 
airways infection involves a relatively small collection of pathogens that are typically acquired in an 
age- dependent sequence, beginning early in life with Haemophilus influenzae followed by S. 
aureus and culminating in chronic infections dominated by P. aeruginosa or Burkolderia cepacia 
complex species (Fig.5). Additional opportunistic pathogens including Stenotrophomonas 
maltophila, Achromobacter xyloxidans and nontubercolous mycobacterium have been recovered 
from adult patients with increasing frequency. 
                      
Figure 4: Schematic view of the pathogenic events that leads P. aeruginosa to establish chronic infection in airways of CF patients [21] 
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Studies on CF respiratory specimens analysed under strict anaerobic culture conditions show that 
anaerobic bacterial species are also present within CF airways in high numbers. The spectrum of 
facultative and obligate anaerobic species includes members of the genera Streptococcus, 
Prevotella, Actinomyces and Veilonella.  
P. aeruginosa is by far the most significant pathogen in CF. Based on immune response in young 
children, infection appears to occur much earlier than believed previously, in fact the mean age of 
detection of an antibody response to P. aeruginosa is 15 months, whereas the mean age of the first 
positive airway culture is 23 months [22] [23]. Risk factors for initial P. aeruginosa airway 
infection in patients with CF diagnosed by new born screening included female sex, homozygous 
∆F508 genotype, and S. aureus precolonization. Up to 80% of patients with CF are eventually 
infected with this organism, and its acquisition is associated to lung tissue deterioration. In 
particular in one longitudinal study that combined the culture of respiratory samples with 
serological infection, more than 97.5 % of CF patients were found to be infected with P. aeruginosa 
by the age of three years. The source of P. aeruginosa isolates in patients has not been clearly 
established even if some patients appear to have acquired infection from social contacts or hospital 
settings, the source of initial acquisition seems to be environmental reservoirs. Thereafter, the 
colonizing bacterial strains persist in the airways of CF patients for several years by adapting their 
phenotype to the host conditions. Paediatric CF patients with respiratory cultures positive for P. 
aeruginosa experience higher mortality (8 years risk of death was 2.6 times higher), an increased 
frequency of infection and hospitalisation for acute respiratory exacerbations, and a decreased lung 
function with a signiﬁcantly lower percent of predicted forced expiratory volume in 1 sec (FEV1) 
when compared to those without P. aeruginosa [24]. Repeated cycles of infection and inflammation 
during post-natal period result in structural abnormalities in CF patients despite essentially normal 
Figure 5: Prevalences of several common respiratory pathogens in CF as a function of age. [12] 
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architecture of the lungs at birth. With established infection, formation of micro-abscesses leads to 
collapse of the distal airways. The reduced ventilation and consequent hypoxia result in airway 
remodelling. This process is considered an important cause of irreversible airway narrowing and 
consequent constitutive airflow limitations in a lung strictly damaged. Pathologic characteristics of 
CF lung disease include squamous metaplasia, submucosa mucus gland enlargement, increase of 
airway smooth muscle mass, and reticular basement membrane thickening highlighted by 
deposition of tenascin and the fibrillar collagens I and III in the sub-epithelial bronchial tissue 
matrix[25-27]Finally, pulmonary insufficiency, mainly due to P. aeruginosa chronic infection, is 
responsible for at least 80 % of CF-related deaths [12].  
S. aureus is the bacterial pathogen most frequently cultured in the paediatric CF population and 
remains an important pathogen throughout adulthood. The CF community is particularly concerned 
about methicillin-resistant S. aureus (MRSA). Some data suggest slightly worse clinical outcomes 
in patients with chronic MRSA infections than in those with methicillin- sensitive S. aureus 
infections, because of greater airflow obstruction, increased hospital admissions and extended 
courses of antibiotics [27]. In addition S. aureus might have a negative effect on post-
transplantation outcomes. Actually it was associated with an increased long term mortality and 
more frequent episodes of  acute cellular rejection within the first 90 days of transplantation. 
Similarly another retrospective study showed that de-novo acquisition of MRSA after 
transplantation resulted in increased mortality compared with transplant patients without MRSA 
infections [28].  
Atypical mycobacteria are sometimes found in airway secretions from CF patients; it remains 
unclear whether this ﬁnding represents true infection in all cases, or is only saprophagous 
colonisation in some patients. Mycobacterium avium complex (72%) and Mycobacterium abscessus 
(16%) were the most common atypical mycobacteria found in a survey of US cystic ﬁbrosis 
centres[29]. 
Other pathogens like S. maltophila or A. xyloxidans, may be present but generally carry no worse 
prognosis. The prognosis dramatically becomes worst after the acquisition of B. cepacia complex 
that cause a sepsis-like syndrome characterized by high fever, bacteremia and a rapid progression to 
severe necrotizing pneumonia leading to death. Recent studies on fungal colonization/infection of 
the CF airway show the presence of Aspergillus fumigatus in up to 50% of subjects and other 
moulds together with yeasts such as Candida, isolated from almost 50 to 75% of CF patients. In 
particular the isolation of A. fumigatus from the airways of children with CF is associated with a 
lower forced expiratory volume in 1 second (FEV1) and an increased risk of pulmonary 
exacerbations requiring hospitalization [30]. Fungal colonization and infection of CF airways late in 
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disease progression is very common and not so surprising considering the exposure to frequent 
broad spectrum antibiotic therapy [31]. In particular Candida colonization was associated with 
worse clinical status (e.g. osteopenia, pancreatic insufficiency) and also with co-colonization with 
P. aeruginosa and A. fumigatus.  
 
B.3 P. aeruginosa genome 
The first completed P. aeruginosa genome sequencing was performed for strain PAO1 [32], derived 
from an Australian wound isolate in 1950s. PAO1 strain is still the major reference strain for 
genetic and functional studies on P. aeruginosa.  
PAO1 genome consists of a 6.264-Mbp circular chromosome encoding 5,570 predicted protein 
coding sequences. It also carries a lot of chromosome-mobilizing plasmids that are very significant 
to the organism ‘lifestyle as a pathogen. The plasmids TEM, OXA and PSE, for instance, encode 
for β-lactamase production, which is necessary for its resistance to antibiotics. The size of the 
PAO1 genome is the result of  genetic complexity (more genes of unique function) rather than gene 
duplication. P. aeruginosa genome has indeed a large number of paralogous groups whose 
members encode distinct genes functions. The significantly higher percentage of these genes groups 
found in P. aeruginosa genome when compared to those present in other bacterial genomes, 
indicates that environmental versatility has favoured a process of expansion of genetic capability of 
P. aeruginosa genome rather than gene duplication. 
Notably there is still one third of P. aeruginosa genome with no attributed homology to any 
previously reported sequences. In detail, only the 6.7 % of P. aeruginosa genome (372 ORFs) are 
known genes with demonstrated functions (confidence level 1) primarily encoding 
lipopolysaccharide biosynthetic enzymes, virulence factors, such as exoenzymes and their secretory 
system, and protein involved in motility and adhesion. The 19 % of P. aeruginosa genome (1,059 
ORFs) are genes with strong homology to those found in other organism with demonstrated 
functions (confidence level 2) including those required for DNA replication, protein synthesis, cell-
wall biosynthesis and intermediary metabolism. The 28.5 % of P. aeruginosa genome (1,590 ORFs) 
are genes with assigned probable function on the basis of similarity to established sequence motif 
(confidence level 3) that belongs to functional classes including putative enzymes (405 genes), 
transcriptional regulators (341 genes), or transporters of small molecules (408 genes). Finally a 
large proportion of the genome (45.8% of ORFs) consists of genes for which no function could be 
determined or proposed (confidence level 4). Of these nearly a third (769 ORFs) shares homology 
to genes with unknown function predicted in other bacterial genomes and the remainder  32% of 
ORFs does not have strong homology with any reported sequence [32]. Consequently there is still a 
  12 
lot of information to be uncovered with regards to the mechanism used by these organism to cause 
disease, with an array of novel virulence factors remaining to be discovered within its genome. 
In addition to PAO1, other 14 P. aeruginosa strain genome are available as completed genomes or 
listed as being draft assemblies or incomplete. The second P. aeruginosa genome sequence was 
published for the strain PA14 [33] a clinical strain more virulent than PAO1, first isolated from an 
human burn patient. Among the other strains whose genome has been sequenced the “Liverpool 
epidemic strain” LESB58 was found to be highly transmissible among CF patients causing severe 
infection even in non CF human hosts [34, 35]. PA7 belongs to a collection of 10 non-respiratory 
clinical isolates (3 from Thailand; 7 including PA7 from the Malbran Institute in Buenos Aires, 
Argentina) that were collected for their unusual resistance patterns sharing only 93.5 % nucleotide 
identity in the core genome with the other sequenced strains [36]. Almost complete genome 
sequences are also available for strains 2192, C3719, PACS2 and 39016 
(www.pseudomonasaeruginosa.com).  
P. aeruginosa has the highest proportion of predicted regulatory genes observed in the sequenced 
bacterial genomes corresponding to the 8.4%. These genes, in addition to the remarkable gene 
complexity, enable P. aeruginosa to evolutionary adapt itself to different environmental conditions 
and hosts. Moreover the bacterium has broad capabilities to transport, metabolize and grow on 
organic substances, numerous iron-siderophore uptake systems and enhanced ability to export 
compounds (enzymes and antibiotics) by a large number of protein secretion and RND efflux 
systems contributing to its intrinsic resistance. Five different classes of secretion systems have been 
described which have been identified as type I secretion system (T1SS) up to type VI secretion 
system (T6SS) [37], with the exception of TIVSS, as well as a number of genes for chemotaxis 
(four chemotaxis systems) and motility [32].  
P. aeruginosa genome is composed by a conserved core component defined as comprising all genes 
present in all sequenced genomes of P. aeruginosa and an accessory component consisting of 
additional strain specific regions. The accessory genome consists of extra-chromosomal elements 
like plasmids and blocks of DNA inserted into the chromosome at various loci. The elements of the 
accessory genome were acquired by horizontal gene transfer from different sources including other 
species or genera. Therefore the P. aeruginosa genome is often described as a mosaic structure of 
conserved core genome frequently interrupted by inserted parts of the accessory genome. This 
mosaic also shows remarkable plasticity. Actually, events of acquisition of new foreign DNA as 
well as larger or smaller deletion events, single nucleotide mutations and even chromosomal 
inversions, potentially affecting parts of the core and/or accessory genome, continuously modify the 
genome. Within the chromosomally integrated islands, very often phages, transposons or IS-
  13 
elements are found. Many elements were irreversibly fixed by secondary mutations or deletions, but 
a few others have retained their mobility and can still leave the chromosomal insertion site and be 
transferred elsewhere, as shown for the elements PAPI-1 and pKLC102 [38]. Among the genomic 
islands of the P. aeruginosa accessory genome, members of the PKLC102 family are highly 
prevalent. They represent a special group of ICEs (Integrative and Conjugative Elements) that 
generally consist of individual semi-conserved DNA blocks. This conserved gene set accounts for 
structural and mobility-related features and conjugal transfer. Individual genes within the islands 
can encode a broad spectrum of different functions, among them catabolic pathways as well as 
virulence effectors.   
A comprehensive comparison of the genomes of  P. aeruginosa strains PAO1, PA14, 2192, C3719, 
and PACS2 [39] led to the definition of so called “regions of genome plasticity” (RGP) that are 
polymorphic strain-specific segments dispersed in the circular chromosome and flanked by 
conserved genes referred to as anchors (Fig.6). These RGP include any region of at least four 
contiguous ORFs that are missing in at least one of the genomes explored. Mathee and co-workers 
in 2008 analysed the genome sequences of three P. aeruginosa strains isolated from CF patients 
(PA2192, PACS2 and C3719). PA2192 exhibits major phenotypic adaptation including conversion 
to mucoidy (due to a non-sense mutation in its mucA gene), while C3719, a representative of the 
Manchester Epidemic Strain, is known for its enhanced virulence and transmissibility. Comparison 
of the annotated genes in the P. aeruginosa PA2192 and C3719 genomes with those in the genome 
of PAO1, PA14 and PACS2, revealed an extensive conservation of a set of genes that are shared by 
all of the strains. There are 5,021 genes that are conserved across all five genomes analysed, with at 
least 70% of sequence identity (Fig.6). In addition, each sequenced P. aeruginosa strain carries 
about 40 RGPs with insertions. The RGPs can be sites of insertions of common or unique genomic 
islands and bacteriophage genomes, or the result of deletions of particular segments of DNA in one 
or more strains. The islands inserted at RGPs often differ among genomes indicating the individual 
evolutionary trajectories of the strains, whilst also maintaining core virulence functions.  
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B.3.1 A different repertoire of P. aeruginosa virulence factors during acute and 
chronic stage of infection 
 
Central to the success of P. aeruginosa infection is the genetic flexibility provided by its large 
genome and its ability to adapt to the pressure imposed by the host mucosal immunity. Actually the 
pathogenesis of P. aeruginosa pneumonia is complex, and the outcome of an infection depends on 
the virulence factors displayed by the bacteria, as well as the host response. Planktonic organisms 
aspirated from the environment up- regulate a specific set of genes involved in motility, proteolytic 
activity and carbon utilization. Later, adaptation results at least in part from the selection of clonal 
lineages containing spontaneously arising mutations. In particular several mechanisms of 
differential gene expression, gene mutation, extensive genomic rearrangements and acquisition of 
large blocks of DNA by co-infecting bacterial species are responsible for generating pathogenic 
variants from the acquired strains.  
 
Figure 6: The P. aeruginosa pangenome. Using the core genes from PA14 as the template, all of the accessory genes from PA2192, C3719, PAO1 and PACS2 
were integrated. The outer circle (gold) indicates the core genes, the second circle shows the functional annotations. The third circle indicates the position of t 
RNAs. The accessory genes in the inner circles are from PA14 (blue), PA2192(green), C3719 (purple), PAO1 (red), and PACS2 (teal). The outer green arrows 
show the positions of rRNAs. [39] 
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During the initial colonization phase a potent array of P. aeruginosa extracellular and cell bound 
virulence factors are critical for the acute phase of infection and then invasion, settlement and 
dissemination throughout the host organism (Fig.7). Among the several surface structures for 
motility and adhesion in biotic and abiotic environments, there are a single polar flagellum, polar 
type IV pili and chaperone/usher pili (cup) fimbriae. Flagella and pili, the motile surface 
appendages of P. aeruginosa, are responsible for bacterial motility, progression towards epithelial 
contact and dissemination throughout the host organism. In particular flagella is considered one of 
the most important virulence factors in acute infection. These complex proteic structures form a 
motile filamentous polar appendage at the surface allowing the swimming movement of P. 
aeruginosa. Interaction with epithelial cells through binding to Toll-like receptors TLR2 and TLR5 
triggers the NFkB inflammatory pathway through activation of the extracellular regulated kinase 
pathway, leading to IL-8 production [40]. Pili or fimbriae are smaller filamentous surface 
appendages involved in twitching motility allowing P. aeruginosa to spread along hydrated surfaces 
rather than swim. This feature facilitates the rapid colonization of the airway, playing a pivotal role 
for the adhesion phase of colonization through the binding to asialoGM component of the epithelial 
cell membrane [40]. 
Lipopolysaccharide (LPS) is the major component of the outer membrane of Gram-negative 
bacteria. It associates a hydrophobic domain, Lipid A, inserted into the phospholipid bilayer, to a 
hydrophilic tail composed of the core polysaccharide and the O-specific polysaccharide. The 
SECRETED TOXINS SYSTEM AND ENZYMES 
FLAGELLA 
TYPE IV PILI 
COMPLETE LPS 




Figure 7:  P. aeruginosa virulence factors during acute and chronic stage of infection. It has been described  that Pseudomonas aeruginosa  during the acute 
phase of infection  is characterized  by a specific arsenal of virulence factors like flagella, type IV pili, type III secretion system, secreted toxins system and 
enzymes and complete LPS. Next the long term colonization of CF airways selects pathoadaptive variants of the pathogen with virulence factors different from 
the initially acquired ones ( a defective LPS, alginate and biofilm production) 
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variable O-specific polysaccharide chains are the basis of antigenic identification of P. aeruginosa 
serotypes. Upon LPS recognition, TLR4 undergoes oligomerization and recruits its downstream 
adaptors proteins MyD88 and TRIF which mediate the activation respectively of proinflammatory 
cytokines and Type I interferon gene (IFNγ) [41]. 
A major virulence factor associated with increased P. aeruginosa aggressiveness is the type III 
secretion system (T3SS). The T3SS allows P. aeruginosa to inject secreted toxins through a 
syringe-like apparatus, directly into the eukaryotic cytoplasm. Several of the translocated T3SS 
effector proteins can modulate innate immune recognition of bacteria or target effector mechanisms 
of the innate immune system. These include Exoenzyme U (ExoU), a phospholipase A2 that can 
inhibit inflammosome activation by P. aeruginosa and that causes rapid necrotic cell death [42]. 
Exoenzymes S (ExoS) and T (ExoT) are enzymes able to inhibit migration and phagocytosis of 
macrophages and neutrophils [43] [44]. Exo Y is an adenylate cyclase that increases intracellular 
levels of cAMP.  
Other virulence factors secreted via T2SS into the extracellular space such as elastase, alkaline 
protease, exotoxin A, and phospholipase C are also liable for invasion and dissemination by 
destroying the protective glycocalix of the respiratory epithelium and exposing epithelial ligands to 
P. aeruginosa and participate in cytotoxicity [45]. Among the alkaline protease secreted, AprA is an 
important virulence factor involved in specific strategies of immune escaping by degradation of the 
central complement protein C3, IFN-gamma and monomeric form of flagellin.  
In addition, P. aeruginosa produces a number of small molecules that are directly inhibitory or 
toxic to immune cells. Pyocyanin a redox-active phenazine can trigger neutrophil apoptosis and it 
may also affect CFTR function by blocking Cl
-
 transport in human bronchial cells [46]. Bacteria 
that cannot produce this molecule are cleared more efficiently from the acutely infected mouse lung 
than isogenic wild type organism [47]. Pyocyanin is associated with disease severity and decline of 
lung function and it contributes to the dominance of P. aeruginosa in the CF lung.  
Pyoverdine is a yellow-green fluorescent siderophore, a small molecule chelating iron from the 
environment for use in P. aeruginosa metabolism. The rhamnolipids, other secreted small 
molecules, cause neutrophil necrosis. It was described that bacterial mutants deficient in their 
synthesis are more rapidly cleared from mouse lungs in a model of agar beads chronic infection 
[48]. In addition rhamnolipid production is positively regulated by signals of the quorum sensing 
(QS), a cell density monitoring mechanism, and their expression is greater when bacteria are in 
stationary phase or high-density growth conditions, such as biofilms. However, their relative 
importance in acute P. aeruginosa infections appears to be less than that of the T3SS or T2SS 
substrates discussed before [49] 
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During the transition from acute to chronic infection several P. aeruginosa factors that exert 
destructive and/or immunostimolatory effects are reduced and most of P. aeruginosa invasive 
functions are selected against in CF chronic infection leading to more persistent phenotypes [50] 
[51, 52](Fig. 7). It has been described that the chronic stage of lung infection is frequently 
associated with a dramatic diversification of the P. aeruginosa persisting clone into various 
morphotypes or niche specialist, a process known as adaptive radiation [53]. These pathoadaptive 
variants are indeed characterized by alterations in P. aeruginosa structures, with respect to the early 
acquired strains. These phenotypic changes may represent an “immune evasion strategy”, necessary 
for long-term colonization of the CF host mediated by P. aeruginosa pathoadaptive lineages.  
In addition, during advanced stage of infection there is an increased expression of genes required 
for survival within the nitrogen-rich, nutrient-deficient CF lung [54] [55] and pathways involved in 
iron scavenging. 
P. aeruginosa is capable of adapting to CF airways by selecting pathoadaptive variants without 
flagella and pili in order to evade immune surveillance and chronically persist in CF patients [56]. 
The loss of engagement by phagocytic receptors, that recognize ﬂagellar components, and the loss 
of immune activation, through ﬂagellin-mediated TLR signalling, indeed reduce host immune 
response. Amiel and colleagues described that loss of P. aeruginosa motility dramatically alters 
immune responses to these bacteria compared to those for motile isogenic bacterial strains and that 
it is the loss of ﬂagellum-mediated motility, but not ﬂagellum expression itself, that results in 
dramatic bacterial resistance to phagocytosis by murine and human phagocytes [57]. Likewise, 
studies in the agar beads murine model by using the P. aeruginosa isolates from patients with CF 
demonstrated that the risk of chronic infection is increased by the absence of pili and ﬂagella [51]. 
These studies provide an explanation for the clinical observation that P. aeruginosa isolates 
obtained from CF hosts often exhibit a non-motile phenotype [58] and indicate how this phenotype 
can confer a survival advantage during chronic infection. In addition P. aeruginosa  down-regulates 
the expression of several cytotoxic factors over the course of infection to establish a long-term 
presence in CF airways, like for example pyocyanin and T3SS. Modification of LPS appears to be 
one of the main factors in the adaptation of P. aeruginosa during chronic CF infection. It is already 
known that P. aeruginosa consistently changes LPS lipid A structure in the evolution from acute to 
chronic infections. Generally production of fully hexa-acylated lipid A is associated with a more 
strong TLR4 mediated inflammatory response while lipid A with lower levels of acylation triggers 
reduced cellular responses [59]. Actually lipid A component isolated from clinical strains of P. 
aeruginosa often results in a blend of different species with a biological activity that might be 
different when compared to single species bioactivity [60]. In 2009 Cigana and co-workers  
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determined the LPS structures of three P. aeruginosa clones isolated from airways of a CF patient 
during a period of 7.5 years. Lipid A acylation was temporally associated with different stages of 
CF infection. Among the three strains, LPS lipid A diversity was observed in the number and 
position of fatty-acid side chains, in particular a predominance of highly acylated LPS structures 
was observed in P. aeruginosa pathoadaptive variants, isolated after years of colonization. Lipid A 
moieties of late adapted strains displayed a reduced immune-modulatory TLR4-mediated activity 
compared to LPS of the clonal strain isolated at the onset of infection. In particular, a weaker NF-
kB and IL-8 inflammatory response in vitro, and reduced neutrophils recruitment and cytokines 
levels were observed in vivo after stimulation with lipid A from late strains with respect to lipid A 
of early strains emphasizing the reduced immune-potential of LPS of late colonizer P. aeruginosa 
strains [60]. Modification of pathogen associated molecular patterns (PAMPs), such as lipid A, but 
also peptidoglycan muropeptides [60], could thus hijack genes involved in innate response 
favouring P. aeruginosa survival. 
An indication of chronic stage of P. aeruginosa infection is the predominance of mucoid strains 
representing the end result of failed innate immunity and an effective bacterial adaptation to the 
host. Mucoid P. aeruginosa is characterized by the over production of alginate, that is an 
exopolysaccharide made of repeating polymers of mannuronic and glucuronic acid. Alginate over-
production has been linked to mutations in a gene cluster designated as  the mucABCD, in particular 
mucA mutants have been isolated from chronically infected CF patients [61]. Surrounding 
conditions in CF patients lungs and host inflammatory response increase alginate synthesis leading 
to conversion to an alginate overproducing mucoid phenotype [62]. Overexpressed alginate protects 
P. aeruginosa against reactive oxygen species and antibiotics [63] [64] [65] and from the host 
defence including scavenging of free radicals released by macrophages, providing a physical barrier 
that impairs phagocytosis, inhibiting neutrophil chemotaxis and complement activation [66]. The 
response of airway epithelia to the stimuli presented by mucoid P. aeruginosa is not pro-
inflammatory and, hence, may not be conducive to the effective elimination of the pathogen [67]. 
Indeed, in vivo studies suggest that clearance of mucoid strains from murine lungs is diminished 
compared with non mucoid strains, indicating improved survival of alginate-producing strains in the 
respiratory tract [68] [69].  
Once a critical mass of bacteria is present in the airways in vivo data indicate that they form a 
cluster of micro-colonies that are encased in a biopolymer matrix called biofilm [70] [71], widely 
diffuse during chronic infection.  P. aeruginosa biofilms are believed to arise in the respiratory tract 
of CF patients through a series of steps beginning with the attachment of planktonic (i.e free 
swimming) P. aeruginosa to epithelial cells or debris within the airway [66]. In the process of 
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biofilm formation, colonies of P. aeruginosa will secrete exopolysaccharides, including alginate, 
resulting in the production of a matrix characterized by a complex architecture of bacterial micro-
colonies. In this microbial community the expression of several virulence factors is coordinated by 
the QS system. This mechanism allows bacteria-to-bacteria cell signalling through highly soluble 
quorum sensors, such as the Pseudomonas homoserine lactone and quinolones, which act in concert 
with specific transcriptional activators. The P. aeruginosa QS system consists of 2 N-acyl-
homoserine lactone (AHL) regulatory circuits (las and rhl) linked to an alkyl-quinolone (AQ) QS 
system. LasR and RhlR are both LuxR transcriptional activators, which activity depends on AHLs 
synthesized via LasI and RhlI, respectively, to drive virulence gene expression. In various infection 
models, mutants defective in QS are significantly less pathogenic than their parental strains 
suggesting that QS systems may be an interesting target for the prevention of acute and chronic P. 
aeruginosa infections [72]. The adaptation process might also be supported by the emergence of 
hypermutable strains characterized by an increased random spontaneous mutation rate, due to defect 
in genes mutS, mutL and uvrD involved in DNA repair or error avoidance systems. In a first work 
published by Oliver et al in 2000, an extremely high prevalence (20% of isolates, 37% of patients) 
of mutator P. aeruginosa was found in chronically colonized CF patients [73]. Regarding the 
genetic basis of hypermutation in P. aeruginosa strains from CF patients, by far the most widely 
investigated mechanism is the MMR system that detects and repairs replication errors including any 
kind of mispairs and short insertions or deletions. Up to 60-90% of the mutator isolates  from CF 
have a defective MMR system, mainly caused by mutation of mutS or mutL. Most important, P. 
aeruginosa hypermutability, which was previously associated with an important biological cost 
[74], turns to be a benefit under selection pressure, such as antibiotic treatments, in a context of CF 
chronic airways infection, and can contribute to lung damage during long-term persistence [75], 
becoming a relevant problem in the management of chronic infections. 
All these findings suggest that immune escape strategies, like mucoid conversion, biofilm growth, 
PAMPs modifications and inhibition of invasive virulence determinants, may confer a selective 
advantage for the establishment of P. aeruginosa chronic colonization and persistence. 
 
B.4 Influence of host genetic make-up influences the outcome of  infection 
diseases 
As shown by studies of genetic susceptibility to infections in human disease, the complexity of 
host-microbe interaction depends on the pathogen with its unique repertoire of virulence factors, but 
also on the host with its specific genetic background. Some of the clearest manifestations of this 
genetic component include the well-known examples of malaria resistance in individuals 
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heterozygous for haemoglobinopathy alleles (HbS) and human immunodeficiency virus (HIV) 
resistance in individuals carrying variance of the viral co-receptor chemokine receptor 5 (CCR5) 
[76] [77]. It has also been described that  particular individuals with polymorphic variants of natural 
resistance-associated macrophage protein 1 (Nramp1) are susceptible to mycobacterial infections 
and that humans harbouring mutations in genes regulating phagocytes activation (IFNGR1, 
IFNGR2, IL12B, IL12RB1 and STAT1) are susceptible to recurrent typhoidal  Salmonella infection 
[78] . In addition, TLR4 gene polymorphisms are associated with susceptibility to various infectious 
and non-infectious disease. Two described polymorphism, Asp299Gly and Thr399Ile, were 
originally associated with the lung response to inhaled LPS in healthy human volunteers [79]. These 
polymorphism belonging to a  specific genetic background, predispose to an increased risk of 
Gram–negative infection [80], sepsis [81], severe inflammatory response syndrome [82], severe 
malaria [83], brucellosis [84], and respiratory syncytial virus disease [85].  
Study of infrequent single-gene effects in humans is useful for better understanding the molecular 
pathogenesis of infection revealing also host defence mechanisms that can potentially be used as 
novel targets for therapeutic intervention. However linkage and association studies show that the 
genetic component of susceptibility to infection is usually complex and multigenic, reflecting the 
plurality of cell types and biochemical pathways involved in both the initial sensing and the 
dynamic response to a pathogen. An evident example of complex disease is CF. Although it is 
recognized as a monogenic disorder, a considerable heterogeneity in its clinical outcome has been 
documented since the description of the disease. Studies on twins and sibs models have determined 
that non CFTR-genetic factors account for more  than 50% of variability in lung disease [86]. The 
hypothesis that variation in phenotype can be explained by allelic variants has been put forward, 
and many studies have attempted to link the type of CFTR mutations to the severity of the disease. 
Good genotype–phenotype correlations have been reported for pancreatic enzyme function [87, 88]. 
However, analysis of the effects of CFTR mutations on pulmonary function, which represents the 
major cause of morbidity and mortality in CF, has failed to establish a strong genotype–phenotype 
correlation [89] and it remains enigmatic how these mutations cause enhanced susceptibility to 
pulmonary infection and how this susceptibility might be prevented [90]. Furthermore there is a 
remarkable heterogeneity among CF patients, in the time of onset and severity of chronic bronco 
pulmonary P. aeruginosa infection [91] even within those carrying the same cftr genotype. 
Identification of additional gene alleles that directly influence the phenotype of CF disease became 
a challenge in the late ‘90ies, not only for the insight it provides into the CF pathophysiology, but 
also for the development of new potential therapeutic targets [89].  
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Two genetic approaches have mainly been explored, the candidate gene approach and the wide 
genome association (GWA) approach. In the candidate gene approach the genes investigated are 
selected from the current understanding of CF lung disease pathophysiology with a special interest 
in factors involved in the inflammatory and infectious response, the ion transports and the 
cytoskeleton. Some examples of most relevant findings show that  polymorphic variants of TGFB1 
have been involved in various respiratory diseases such as pulmonary fibrosis, asthma, COPD, and 
also associated with more severe CF lung disease [92], with some controversial findings maybe 
correlated to population ancestry and environmental factors [93]. Also three polymorphism found in 
IL8 gene were associated with CF pulmonary disease severity [94]. MBL2 is an innate immune 
protein accumulated in the lung during acute inflammation that plays a major role in infectious 
disorders binding several bacteria including P. aeruginosa and S. aureus. Chalmers and colleagues 
correlate MBL2 deficiency alleles to  an earlier P. aeruginosa acquisition, reduced pulmonary 
function among adults and increased rate of death or requirement of lung transplantation. 
Polymorphism located in TLR4 and TLR5 genes instead did not show significant association with 
lung function or age at first P. aeruginosa acquisition in CF young patients [95].  
In order to overcome the limitations linked to small sample size and poor study design of the 
candidate gene approach, linkage analysis program and GWA studies were set up. The wide 
genome approach includes indeed linkage analysis and association analysis, both based on 
polymorphism linked to the gene responsible for disease susceptibility. By linkage analysis, familial 
segregation of disease can be followed through the phenotype and linkage can be established 
between phenotypes and genetic markers (single nucleotide polymorphism, dinucleotide repeats) 
thereby defining the chromosomal region harbouring the genes predisposing to the disease. 
Association studies are used to analyse in case control series or families a particular marker allele 
transmitted more frequently than expected under segregation ratio from parents to affected 
offsprings. The advent of large-scale genomic studies, where several thousand polymorphisms 
could be measured at once, allow indeed an “uninformed” look at phenotype/genotype correlation. 
For instance, Gu et al reported that IFRD1 polymorphism may be involved in the severity of CF 
lung disease through the regulation of neutrophil effector function [96]. The genome wide 
association approach therefore represents an unbiased yet fairly comprehensive option that can be 
attempted even in the absence of convincing evidence regarding the function or location of the 
casual genes. Indeed this kind of analyses is conceptually a revolution whereby several thousand 
genomic polymorphisms could be correlated to specific phenotype. Understanding phenotypic 
variation in relation with that found in genotype offers promise to tailor treatment to the best of 
each patient’s condition, setting the basis for “personalized medicine” strategy.  
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However this kind of studies will require to collect new large cohorts of clinically well-
characterized   patients, like in CF disease [97]. In addition controlled and standardized 
investigations of the genetics of susceptibility to infections are very cumbersome in humans 
because of environmental and other confounding factors (i.e pathogen interaction, incomplete 
penetrance, population heterogeneity and phenotypic variants) that are numerous and difficult to 
control in human studies. To address them, patients cohorts will have to be stratified into 
increasingly smaller groups reducing the efficacy of association analyses. For all these reasons, 
laboratory mouse models provide a valuable complementary tool in order to dissect the genetic 
architecture of host susceptibility toward many infectious agents. 
 
B 4.1 Inbred mouse strains model  
Experimental animal model are widely and successfully used in order to understand the genetic 
basis of differential susceptibility to infection. 
The advantages in the experimental use of these mouse strains are the accurate reproducibility of 
several aspects of the human disease, including pathogenesis (tissues and cells involved, types and 
progression of lesions developed) and physiological responses (inflammation, immunity), and the 
possibilities to study these functional responses in an environment in which pathogen associated 
variables such as strain, virulence, dose and route of infection can be carefully controlled [78]. 
There exist more than 200 commercially available, phylogenetically diverse inbred mouse strains 
(Fig.8) that contain enough genetic diversity to identify individual strains showing major 
differences in response to a specific infection [98].  
 





Figure 8:  Inbred mouse strains 
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These inbred strains are genetically pure (homozygous at all their loci with an  average at least of 
98.6 % after 20 generations) and can therefore be sampled repeatedly allowing multiple serial 
analyses of different aspects of pathogenesis and host response. The availability of a complete and 
annotated mouse genome, high-density single nucleotide polymorphism (SNP) maps and the 
possibility of germ-line modification make the mouse an experimental model of choice for the 
genetic analysis of susceptibility and response to infection with several types of pathogen.  
Genetic studies in mouse models may identify genes, proteins, and biochemical pathways central to 
the host defence that can be validated in parallel studies in human populations from area of endemic 
disease.  
The principal approaches to identify individual host genes impacting pathogenicity and host 
response to infections in mice are “reverse genetics” and “forward genetics”. The former approach 
is based on the use of knock-out mice deleted in specific genes in order to dissect their role in host 
response. Reverse genetics is a classical and largely used analyses method, but carries some 
inherent limitations which include high embryonic lethality, absence of a detectable phenotype due 
to genetic redundancy in the pathway targeted or compensatory mechanism [98]. The forward 
genetic approach is based on the identification of mouse strains that exhibit an unusual or extreme 
response to infection, being highly resistant or highly susceptible. The genetic component of the 
trait is then analysed in standard informative crosses to determine inheritance and complexity. In 
general, a genome-wide scan is conducted to locate the gene in the case of monogenic trait or major 
quantitative trait loci (QTL) in the case of complex trait. 
Actually forward genetic analyses of inbred mouse strains provided several insights into host 
response to  variety of microbial pathogens, including bacteria, viruses and parasites [78], 
highlighting large difference in susceptibility to infection due to the combinatorial effect of genetic 
loci and environmental factors. Indeed host genetic variations play a significant role in conferring 
predisposition to infection. For instance one study described a divergent phenotype among different 
inbred mouse strains in term of  susceptibility to S. aureus infection. Whereas C57BL/6 mice were 
the most resistant in terms of control of bacterial growth and survival, A/J, DBA/2 and BALB/c 
mice were highly susceptible and succumbed to S. aureus infection shortly after bacterial 
inoculation. Other strains (C3H/HeN, CBA and C57BL/10) exhibited an intermediate susceptibility 
[99]. A remarkable difference in susceptibility to Streptococcus pyogenes infection was found 
among different inbred mouse strains after intravenous infection with this pathogen. While CBA/J, 
C3H/HeN, A/J, PwD/Ph mice were the most susceptible strains, C57BL/6J mice displayed an 
intermediate susceptibility and DBA/2J and BALB/cJ mice were the most resistant strains [100]. 
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Also in the  genetic studies of  susceptibility to Candida albicans infection, mice with different 
genetic background show a different response. In particular C57BL/6J, BALB/cJ, CBA/J and 
DBA/1 mouse strains are described as resistant while A/J, DBA/2J NZB/J and AKR/J  are described 
as susceptible to  C. albicans infection. Focusing on the extreme susceptibility of  A/J mice, Tuite 
and colleagues demonstrated that this phenotype  is due to the absence of an adequate inflammatory 
response describing a partial correlation of susceptibility with a deficiency of C5 complement 
component [101]. C5 is a downstream component of the activation cascade of complement system. 
Cleavage of C5 by C5 convertase results in the generation of the potent anaphylotoxin C5a (strong 
chemoattractant of neutrophils and macrophages) and the formation of C5b-9, the membrane attack 
complex (MAC) that can directly kill pathogen. In addition, C5 deficiency is associated with 
susceptibility to other type of infections, including L. monocytogenes [102], Bacillus Anthracis, 
Aspergillus fumigatus, but not for example S. aureus, in this case the susceptibility of A/J mice is 
not strictly correlated to C5 deficiency [103].  
It was also well described  that different mouse genetic background influences the response to 
influenza A virus infections, highlighting how the course and the outcome of  an influenza virus A 
infection is influenced by several viral and host factors [104] [105]. 
Finally  studies relative to susceptibility to P. aeruginosa lung  infection described a different 
susceptibility among different inbred mouse strains, in terms of survival ([106], magnitude of 
inflammatory response [107], [108],  [109], bacterial clearance and lung damage [110]. 
It is clear that host genetic make-up influence the outcome of  infectious  diseases. Furthermore the 
severity of pulmonary disease induced by P. aeruginosa may vary from one CF patient to another 
even carryng the  same CFTR mutations, suggest that host genetic background may influence the 
response to P. aeruginosa infection. This also suggests that the host genetic background  in a 
different category of patients at high risk to develop P. aeruginosa infection (i.e,  
immunocompromised, transplants recipients and neutropenic), maybe contribute and provides new 
insights in dissecting the mechanism at the base of the response to this pathogen. 
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C. Aim of the Project 
Pseudomonas aeruginosa is the fourth most commonly isolated hospital pathogen, multidrug 
resistant, difficult to-treat and potentially deadly causes of pneumonia. Patients at risk of acquiring 
P. aeruginosa are particularly those with a compromised immune system, due to 
immunosuppressive therapies or underlying diseases such as cancer, AIDS or the hereditary disease 
cystic fibrosis (CF). P. aeruginosa-host interaction is driven by several factors including the 
bacterial phenotype and the host genetic make- up. This interaction may be extremely complex and 
difficult to dissect experimentally. This complexity is based on an equilibrium between the 
pathogen and the host that mainly depends on: the pathogen factors  including  life cycles, invasion 
processes, and specific repertoire of virulence factors, and the host factors including genetic 
background and defence mechanisms. Therefore both P. aeruginosa virulence factors and host 
genetic background contribute to determining the outcome of the infection that might be clearance 
of the microbe, asymptomatic colonization and persistence or active infection with the development 
of resulting pathology.  
From the bacterial side, there is still one third of the P. aeruginosa genome with no attributed 
homology to any previously reported sequences with only 6.7% of its genes having a function 
verified experimentally. Consequently, there is still a lot of information to be uncovered with 
regards to the mechanisms used by this organism to cause disease. From the host side, there is a 
remarkable heterogeneity among CF patients in the time of onset as well as in the severity of P. 
aeruginosa lung disease, indicating that the host genetic make-up has major influences in 
controlling the infection. The genes responsible for such variation are unknown.  
The main objectives of this thesis are: 
1) to identify and validate novel P. aeruginosa virulence factors contributing to disease 
pathogenesis in a multi-hosts model system. A library of 57,360 P. aeruginosa Tn5-mutants 
was generated and screened for phenotypic virulence traits (swarming, pyocyanin, and 
protease). A selection of virulence attenuated mutants were then tested for their toxicity in 
non-mammalian models, namely Caenorhabditis elegans and Drosophila melanogaster. In 
this thesis, a selection of Tn5-mutants were tested for invasion and IL-8 production in 
immortalized respiratory A549 cells. Mortality, inflammation and lung pathology were 
scored after acute infection of eight selected P. aeruginosa mutants in C57BL/6 mice. Five  
out of eight mutants were significantly attenuated in inducing mortality.  This screening 
generated a list of virulence-related genes relevant for pathogenicity in multi-hosts and 
favour much-needed insights into aspects of P. aeruginosa/host interaction. 
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2) to seek to which extent the host genetic background may influence the onset, progression, 
pathophysiology and ultimate outcome of P. aeruginosa infection in different inbred mouse 
stains. In this thesis nine inbred mouse strains, namely A/J, BALB/cJ, BALB/cAnNCrl, 
BALB/cByJ, C3H/HeOuJ, C57BL/6J, C57BL/6NCrl, DBA/2J, and 129S2/SvPasCR, were 
infected P. aeruginosa by acute infection and scored for body weight, mortality and mean 
survival time. Based on these results  the nine inbred strains were classified for their different 
response to infection and  two deviant clinical phenotype. Next one of the most susceptible 
and one of the most resistant strains were examined in a time course analysis  for their 
deviant clinical and immunological phenotype in terms of bacterial load, inflammation and 
lung pathology. Our results indicated that host genetic make-up may have a role in the 
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D. Main Results 
D.1 Overview of a strategy for identification and validation of new P. aeruginosa 
virulence factors  
In order to identify  and validate novel P. aeruginosa virulence factors a de novo analysis of the 
whole genome combined with  a multifaceted approach, based on a sequential cascade of models 
(Fig.9), was used.  
First in collaboration with Prof. Miguel Camara of University of Nottingham, a transposon library 
was generated using a Tn5 mutagenesis approach that is considered a powerful tool to examine a 
large number of mutants. Using this technology, it was estimated that around 60.000 mutants could 
be generated with 95%  chance of disrupting any given gene of 327 bps according to Liberati [111] 
To perform this mutagenesis pLM1 plasmid was used  due to the high transposition efficiency of 
this Tn5- based vector in P. aeruginosa PAO1-L strain. A total of 57,360 Tn5 mutant strains were 
obtained by conjugation. All the mutants generated were tested individually for attenuations in 
swarming motility, the loss of the blue pigment pyocianin and reduction in protease production 
(Fig.9). Among a total of 57,360 mutant strains, 404 mutants were found to be attenuated in these 
virulence factors. These mutants showing pleiotropic phenotypes were tested in a second stage 
screening by our collaborator of University of Zurich Prof. Leo Eberl using the non-mammalian 
host models Caenorhabditis elegans and Drosophila melanogaster. From a total of 404 transposon 
mutants tested, 114 mutants were mapped in order to identify  the insertion sites  and to eliminate 
mutants redundancy. The numbers of mutants with attenuated virulence in at least one non- 
mammalian model were reduced  to 71 candidate genes and to 43 mutants attenuated in both non 
































The 43 mutants were analysed for their cytotoxicity by our collaborator Prof. Gerd Doring of  
University of Tubingen. My work focus on the validation of  a selection of  28  attenuated  mutants 
in in vitro assays in order to evaluate their invasion capacity and pro- inflammatory induction of IL-
8 cytokine in immortalized respiratory A549 cells. The screening generated a list of genes 
attenuated in the multi-host system listed in a Genomic Target Database and grouped by a ranking 
score based on the results obtained by phenotypic screening for virulence, validation in C. elegans, 
D. melanogaster and  in vitro models. In addition through an in silico analysis, a score was 
calculated considering the conservation in all sequenced P. aeruginosa genomes (LESB58, PA14, 
PA7, 2192, C3719, PACS2), in Burkholderia cenocepacia J2315 and Escherichia coli K12, and 
assigning a negative value in case of homology to human genome.  
Finally eight stable in frame deletion mutants were generated by double homologous recombination 
system  for the genes selected, including  those not attenuated in virulence as  controls, and 
validated for their virulence in a mouse acute infection model. These genes belong to several 
functional classes including hypothethical, catabolism regulation (catabolite repression control 
protein, crc), iron uptake (heme oxygenase, bphO), quorum sensing (3-oxo-C12-homoserine lactone 
Fig.9 Screening strategy leading to new virulence factors identification and validation 
  29 
acylase, pvdQ). In addition, the previous screening identified also five mutants highly attenuated in 
all the assays and conserved among all P. aeruginosa sequenced genomes. Being unknown or 
poorly studied, these genes could be relevant to further dissect P. aeruginosa virulence, and might 
represent novel targets for future antimicrobials development. The results of these five mutants are 
not shown in this thesis because of patent issues. 
 
D1.1 Validation of 28 selected P. aeruginosa mutants in immortalized cell lines  
We screened 28 P. aeruginosa Tn5-PAO1 mutant strains, selected by the cytotoxicity assay, for 
their capacity to invade the immortalized cell line A549 and to induce IL-8 release. An antibiotic 
exclusion assay was used to evaluate bacteria internalized in the cells after infection. As to IL-8 
release, it was measured in the supernatant of cells infected with the mutants by ELISA. 
Results show that 19 Tn5-PAO1 mutants were significantly attenuated in their capacity to invade 
A549 cells in comparison to the wild type PAO1 (Fig.10A) (PAO1-L wild type vs PA3867 and 
PA2414, p<0.05; PAO1-L wild type vs PA4916, p<0.01; PAO1-L wild type vs PA0914, PA2873, 
PA5332, PA2385, PA5203, PA4767, PA1634, PA3449, PA1799, PA4768, PA3512, PA3799, 
PA3761, PA4116, PA4059 and PA5156,  p<0.001, Student’s t-test). 
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IL-8 release was significantly attenuated in A549 cells infected with 20 Tn5-PAO1 mutants in 
comparison to those infected with wild type PAO1 (Fig.10B) (PAO1 wild type vs PA3622, 
PA0914, PA2873,PA2414, PA2385, PA5203, PA3460, PA4768, PA3512, PA3799, PA3139, 
PA3761, PA4116 and PA3613 p<0.05; PAO1 wild type vs PA5332, PA3449,PA3623, PA3058, 
PA4059, PA3522  p<0.01, Student’s t-test). Overall, 17 Tn5-PAO1-L mutants were attenuated both 
in invasion and IL-8 release in comparison to the wild type PAO1-L. 
For the next stage of analysis eight in frame stable deletion  mutants (ko) were constructed by 
double homologous recombination in order to confirm their role in virulence. Mutants were checked 
Fig.10 Invasion and IL-8 release in A549 cells. A) Invasion and B) IL-8 release were evaluated in A549 cells, respectively by antibiotic exclusion 
assay and by ELISA, after infection with PAO1-L wild type and Tn5 mutants. In details, 1.6 x 105 A549 cells/well for the antibiotic exclusion assay and 
6 x 105 A549 cells/well for the supernatant collection assay were infected with PAO1-L wild type and the Tn5 mutants  in exponential growth at 
multiplicity of infection (MOI) of 100 for antibiotic exclusion assay, and at  MOI of 1 for IL-8 measure. After two hours, we treated the samples with 
polymyxin B for the antibiotic exclusion assay at final concentration of 100μg/ml and amikacin for IL-8 measure at final concentration of 1mg/ml. The 
abovementioned antibiotic concentrations have demonstrated killing activity exclusively against extracellular bacteria, thus preserving internalized 
bacteria. For the invasion assay after 2 hours of antibiotic and after osmotic lysis of the cells, we plated serial dilutions of the samples on TSA. The day 
after, colony forming unit (CFU) were counted to determine the number of bacteria internalized in the cells. For IL-8 measure, after 24 hours we 
collected and centrifuged the culture media and stored the supernatants at – 80°C. Samples were then assayed by ELISA. Data, from three independent 
experiments performed in triplicates, are expressed as mean +/- SD. *p<0.05, **p<0.01, ***p<0.001 in the Student’s t-test.  
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by sequence analyses  and were further validated  using quantitative in vitro analysis for attenuation 
in virulence traits, C. elegans and D. melanogaster killing curves, cell invasion and cytokine 
production assays. The selected mutants were pvdQ and crc as they were attenuated in in vitro 
assays   and in  non-mammalian  models,  kdpB, bphO and PA2414 as they were attenuated in all in 
vitro screenings and in non-mammalian models except for D. melanogaster model, PA4916 as it 
was attenuated in all in vitro and  in non- mammalian models except for C. elegans model and 
finally PA5156 and PA3613 as they did not show attenuation in  both non-mammalian host models 
but showed again different levels of attenuation in the others in vitro assays. In particular, the  
results of invasion and secretion of the pro-inflammatory cytokine IL-8 in  A549 cells challenged 
with the eight mutants are shown (Fig. 11). Seven out of the selected ko mutants were significantly 
attenuated in term of invasion capacity (PAO1-L wild type vs kdpB, pvdQ, bphO, crc and PA5156 
p<0.001; PAO1-L wild type vs PA4916 p<0.01; PAO1-L wild type vs PA2414 p<0.05) and six 
mutants were attenuated in IL-8 release (PAO1-L wild type vs bphO and PA5156 p<0.01; PAO1-L 
wild type vs kdpB, pvdQ, crc and PA2414 p<0.05) in comparison to the wild type PAO1-L 
(Fig.10A and B). PA3613 resulted not attenuated in invasion capacity and IL-8 protein release. 
Finally these mutants were tested in the mouse model. 
 
  32 




D1.2 Validation  of eight  P. aeruginosa mutants in a mouse model of acute lung 
infection 
A mouse model of acute lung infection, was established in C57BL6/NCrlBR mice by intra-tracheal 
injection of planktonic bacteria to screen the eight stable deletion  mutants selected from the 
previous screenings in vitro and in non- mammalian models. First a dose response assay was 
performed using wild type PAO1-L to choose the correct dose for the screening. So, escalating 




 CFU of wild type PAO1-L were used to challenge male 
C57BL6/NCrlBR mice to determine the relative range of susceptibility (Fig.12). The dose of 5x10
6
 
CFU/mouse caused mortality in 80% of the infected mice and it was chosen as the first lethal dose. 
 
Fig.11 Invasion and IL-8 release in A549 cells of 8 selected Tn-5 mutants. A) Invasion evaluated by antibiotic exclusion assay and B) IL-8 
release by ELISA were evaluated in A549 cells after infection with wild type and ko mutants. Data, from three independent experiments 
performed in triplicates, are expressed as mean +/- SD. *p<0.05, **p<0.01, ***p<0.001 in the Student’s t-test.   
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Next, C57BL/6NCrlBR mice were intratracheally injected with the dose of 5 x 10
6
 of type PAO1-L 
and mutants and survival monitored up to 96h (Fig.13A). While wild type PAO1-L was totally 
lethal within 36h, the lethality of mutants was significantly lower and temporally shifted (Fig.13A). 
Five ot of eight mutants were significantly attenuated in inducing mortality when compared to wild 
type PAO1-L (wild type PAO1-L vs pvdQ, bphO and crc p<0.001; wild type PAO1-L vs PA4916 











Fig.12 Lethality of different doses of wild type PAO1-L in a mouse model of acute lung infection in C57BL6/NCrl mice. C57BL6/NCrl  eight weeks 
old purchased from Charles river laboratory, were  anesthetized with 375 mg/kg of Avertin (2,2,2-tribromoethanil), intubated with a 22-gauge venous 
catheter and intratracheally injected with different doses of planktonic wild type PAO1-L and survival monitored up to 96 hours (* p <0.05 **p<0.01, 
Mantel-Cox test).  



























Furthermore, histopathological analysis (Fig. 13B) showed that wild type PAO1-L strain induced 
slightly highest inflammation and haemorrhage in comparison to crc  and pdvQ mutants. The area 
infiltrated by inflammatory cells was significantly higher in the lungs infected by wild type PAO1-L 





Fig.13 Virulence of P. aeruginosa PAO1-L and a selection of mutants in a mouse model of acute lung infection in C57BL/6NCrl mice. 
C57BL6/NCrl  eight weeks old purchased from Charles river laboratory were intratracheal injected with 5x106 CFU of PAO1-L wild type or mutants. 
A) Survival was monitored up to 96 hours. Two independent experiments were pooled. Statistical analysis was calculated for pair wise comparisons 
between wild type and mutant strains. *p<0.05, **p<0.01, ***p<0.001, Mantel-Cox test. B) Lung histopathology was performed after 24h from 
infection for wild type PAO1-L, pvdQ  mutant and crc ko mutant. C) Quantification of infiltrated areas as a percentage of total tissue area with mean ± 
SEM is shown. Statistical analysis was calculated for pair wise comparisons between wild type and mutant strains. ***p<0.001, Mann-Whitney. 
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D.2 Genomic Target Database of P. aeruginosa virulence factors 
 
Overall all the results obtained from this sequential screening model were used to generate a 
genomic target database. An exemplificative picture of this database is shown below (Table 1). All 
listed factors in the database are genes involved in virulence identified by insertional mutagenesis 
and may be essential for in vivo infection. In addition sequence analyses showed that these genes 
are conserved among strains of different origin, thus representing good alternative candidates 
targets for antibiotic therapies in the future.  
So far, 28 Tn5 and eight stable deletion mutants were validated in different model systems and five  
stable deletion mutants  were attenuated in murine model. It should be noted that some mutants 
attenuated in C. elegans were not attenuated in the mouse model. Our data thus indicate that 
identification of virulence genes carried out mainly in vitro does not imply that they are relevant for 
their pathogenesis in vivo, suggesting a host-specific response to P. aeruginosa, and the necessity to 





























































































































































































































































PA2385 pdvQ 1 94-99% NSH NSH + + + + + + - + + + 10 
PA2414 L-sorbosone dehydrogenase 2 94-99% 25% NSH + + + + - + + + + - 10 
PA1634 kdpB 2 98-100% 60% 28% + + + + - + + + + - 10 
PA5332 crc 1 100% 40% 29% + + - + + + + + + + 9 
PA4116 bphO 1 85-100% NSH NSH + - + + - + + + + + 9 
PA4916  4 97-99% 66% NSH + + + - + + - + + + 9 
PA5156  4 94-99% 26% NSH + + + - - nd nd + + + 7 
PA3613  4 97-100% NSH NSH - + + - - - - - - - 4 
 
 *P. aeruginosa sequenced genomes (LESB58, PA14, PA7, 2192, C3719, PACS2) 
                             NSH   not significant homology 
                              nd   not determined 
                     +   attenuated in comparison to wild type PAO1 







Table 1. Genomic target database (GTD) generation. The genomic target database was generated by attributing a score to the results obtained by 
phenotypic screening for virulence, validation in C. elegans, D. melanogaster, in vitro models and murine model of acute lung infection, and to the in 
silico analysis.Score criteria: first, a score for homology to each sequenced genome was evaluated, then an overall score was assigned to each mutant as 
indicated by following criteria. Homology  to single P. aeruginosa sequenced genome (LESB58, PA14, PA7, 2192, C3719, PACS2), score 1(90-100%), 
score 0,5(75-90%), score 0 (0-75%). Overall homology score, score 2 (sum of all conservation scores ≥5,5) score 1,5 (sum of all conservation scores = 
4,5-5), score 1 ( sum of all conservation scores 4-3,5) score 0,5 (sum of all conservation scores ≤ 3&>0) score 0 (sum of all conservation scores= 0) 
Homology to B. cenocepacea J2315 genome: score 1(70-100%) score 0,5 (55-70%), score 0 (0-55%). Homology to E. coli k 12 genome score 1(70-
100%) score 0,5 (55-70%), score 0 (0-55%). Homology to human genome, score 0 (no homologs) score -1(presence of homologs)   
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D.3 Survival and body weight of P. aeruginosa-infected inbred mice is strongly 
dependent upon genetic background.  
For the second aim of my thesis, nine different inbred mouse strains, namely A/J, BALB/cJ, 
BALB/cAnNCrl, BALB/cByJ, C3H/HeOuJ, C57BL/6J, C57BL/6NCrl, DBA/2J, and 




of planktonic P. aeruginosa clinical isolate AA2 
via intra-tracheal injection, and monitored for change in body weight and mortality over a period of 
seven days. As shown in Fig.14, a wide-range of survival and weight loss were observed among 
different inbred mice. The most deviant survival phenotypes were observed for A/J, 
129S2/SvPasCRL and DBA/2J showing high susceptibility and BALB/cAnNCrl and C3H/HeOuJ 
showing more resistance to P. aeruginosa infection. BALB/cJ, BALB/cByJ, C57BL/6J, 
C57BL/6NCrl showed intermediate phenotype. In more detail, susceptible A/J, 129S2/SvPasCRL 
and DBA/2J died within the first two days of infection, showed a mean survival time of around one 
day and a rapid and fatal decrease of body weight (Fig. 14A, B and C). Within the susceptible mice, 
A/J were significantly different compared to DBA/2J and 129S2/SvPasCRL showing a faster 
decrease of body weight at day one (Table S1, submitted paper ) and a kinetic of death significantly 
more rapid (A/J vs DBA/2J, p <0.01; vs 129 S2SvPAsCrl , p<0,05 Mantel-Cox test) (Fig.14A). 
Resistant mice BALB/cAnNCrl and C3H/HeOuJ showed a significant lower susceptibility to P. 
aeruginosa infection compared with A/J, DBA/2J and 129S2/SvPasCRL with cases of 
survival(C3H/HeOuJ and BALB/cAnNCrl vs 129S2SvPasCrl, p<0.001; vs DBA/2J p<0.01; vs A/J 
p< 0.0001, Mantel-Cox test), a mean survival time of at least three days and a progressive weight 
recovery of the survivors at day seven (Fig.14). Within the resistant mice, BALB/cAnNCrl and 
C3H/HeOuJ were not significantly different for the body weight, kinetic of death and survival time 
(Table S1 of submitted paper and Fig. 14). The above described differences in resistance and 
susceptibility of most deviant inbred mice were confirmed by infecting with a lower P. aeruginosa 




( Table S2 and Figure S1, submitted paper).  
 



























D4. Impaired cell-mediated immunity leads to faster replication of P. aeruginosa 
in A/J mice when compared to C3H/HeOuJ.  
Next, one of the most susceptible and resistant mouse strains were characterized for their deviant 
clinical and immunological phenotypes after P. aeruginosa AA2–induced acute pneumonia. The P. 
aeruginosa load and immune response of infected mice in terms of leukocyte recruitment, 
myeloperoxidase activity, and local cytokine production in the airways were investigated in A/J and 
C3H/HeOuJ mice during an early time course (6, 12 and 18 hours post-infection). Starting from a 
challenge of 5x10
6 
CFU, significant increase of total bacterial load of 2 log10 CFU (4.1x10
8
) at 18 
hours in the lung of susceptible A/J mice was observed indicating an uncontrolled replication of 
bacterial cells (Fig. 15A). Conversely at the same time points, the bacterial load in the lungs of 
resistant C3H/HeOuJ mice was unchanged in respect to the initial inoculum (6.9 x 10
6
) suggesting 
that resistant mice are able to keep in check the infection. A/J susceptible and C3H/HeOuJ resistant 
mice were significantly different in their bacterial load at all-time points( A/J vs C3H/HeOuJ, 
Fig. 14 Survival, body weight and mean survival time after P. aeruginosa infection in inbred mouse strains. 
A/J (n=22), BALB/cJ (n=9), BALB/cAnNCrl (n=8), BALB/cByJ (n=12), C3H/HeOuJ (n=26), C57BL/6J (n=10), C57BL/6NCrl (n=15), DBA/2J (n=12), and 
129S2/SvPasCRL (n=12) mice were inoculated with 5x106 CFU of P. aeruginosa clinical isolate AA2, and monitored for survival (A) and weight change for a period of 
seven days after infection (C). In addition, mean survival time was calculated based on the survival curve (B). The data are pooled from two to four independent 
experiments. Statistical significance by Mantel-Cox test for survival (A), One.way ANOVA with Bonferroni’s Multiple comparison test (B) for mean survival time 
(*p<0.05, **p<0.01, ***p<0.001). Statistical significance by  Two-way ANOVA, with Bonferroni’ Multiple comparison test  for body weight is reported in Table S1A. 
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p<0.001, Mann-Whitney U test). Similar differences were also observed in different airways 
compartments as assessed by Bronco Alveolar lavage Fluid (BALF) (Fig. 15B) and lung 
homogenate  analysis (Fig. 15C).  
Leukocyte recruitment in the BALF of susceptible A/J mice early after P. aeruginosa infection was 
significantly lower than C3H/HeOuJ resistant mice (Fig. 15D). Furthermore, while the low 
leukocyte numbers remained stable in A/J during 18 hours, their recruitment in C3H/HeOuJ 
increased and reached the pick at 12h.  
 








In particular, a significant increase in neutrophil levels for C3H/HeOuJ, compared to A/J was 
observed during 18h (p<0.001, Mann-Whitney U test) (Fig. 16A). The higher level of MPO activity 
in the BALF of C3H/HeOuJ compared to A/J supported these data (Fig. S2, submitted paper).  
Macrophages were also significantly higher in the lung of C3H/HeOuJ mice compared to A/J mice 
at 12 hours post infection (p<0.05, Mann-Whitney U test), but no striking differences were present 
Fig. 15 Early time course of P. aeruginosa load and leukocytes recruitment in BALF and lung of susceptible A/J and resistant C3H/HeOuJ mice.  
A/J (n=12, for each time) and C3H/HeOuJ (n=12, for each time) mice were challenged with 5x106 CFU of AA2 clinical stain and analysed during a time 
course post-infection. Bacterial loads in the total lung (A) including broncoalveolar lavage  (BAL) (B) and lung homogenate (C) were counted at 6, 12 
and 18 hours in surviving mice. BAL fluid was extracted with a 22-gauge venous catheter by washing the lungs with RPMI with protease inhibitors. Dots 
represent CFU per lung in individual mice and horizontal lines represent median values reported in log scale. Total leukocytes were analyzed in BALF of 
P. aeruginosa infected mice (D). Bars represent median values. Blue is referred to A/J and green to C3H/HeOuJ. The data are pooled from two 
independent experiments. Statistical significance by Mann-Whitney U test is indicated: **p<0.01, ***p<0.001,  ****p<0.0001. 
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at 6 and 18 hours post infection (Fig. 16B). Lymphocytes and epithelial cells were not statistically 
different during the time course analysis (Fig. 16C and D).  
 
 







When CFUs and neutrophils recovered in the BAL fluid were plotted together, a distinct trend was 
observed in A/J and C3H/HeOuJ mice during 18 hours of infection. Fig 17 showed a lower number 
of neutrophils recruited and a higher number of P. aeruginosa CFUs in A/J mice in comparison to 
C3H/HeOuJ mice. In particular, looking at the ratio of  P. aeruginosa CFUs and neutrophils, 
significant differences were found (Fig S3, submitted paper). During the whole time-course, the 
ratio between CFUs and neutrophils was significantly lower for C3H/HeOuJ mice when compared 
to A/J mice, indicating a higher capacity of C3H/HeOuJ mice to control P. aeruginosa infection.  
 
 
                    
Fig.16 : Lung inflammatory response after P. aeruginosa infection in susceptible A/J and resistant C3H/HeOuJ.  
The number of neutrophils (A), macrophages (B), lymphocytes (C) and epithelial cells (D) recruited in the airways were determined in the BALF from 
A/J (n=12) (blue bar) and C3H/HeOuJ (n=12) (green bar) mice after 6, 12 and 18 hours of P. aeruginosa infection with 5x106 CFU of AA2 clinical 
isolate. Differential cell count was performed on cytospins stained with Diff Quick The data are pooled from two independent experiments. Statistical 
significance by Mann-Whitney U test is indicated: *p<0.05, **p<0.01, ***p<0.001.  
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D4.1 Cytokines and chemokines profile in the airways of A/J and C3H/HeOuJ mice 
To better characterize the airway inflammatory response of the two deviant inbred mouse strains, 
we measured the concentration of a large panel of twenty-three cytokines and chemokines in murine 
lung homogenates. As shown in Table 2, the overall levels of proinflammatory citokines were 
significantly higher in the lung of A/J mice respect to C3H/HeOuJ mice and reach significance for 
interleukin 1α (IL-1α), interleukin 3 (IL-3), interleukin 6 (IL-6), interleukin 10 (IL-10), 
interleukin12p40 (IL-12p40), interleukin 13 (IL-13), interleukin 17 (IL-17), granulocyte colony-
stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), 
interferon γ (IFN-γ), murine Keratinocyte chemoattractant chemokine (mKC), Monocyte 
Chemoattractant Protein 1  (MCP-1), Machrophage Inflammatory Protein-1 alpha/beta ( MIP-1α 
and MIP-1β ) in at least one time point. Other cytokines, tumor necrosis Factor α (TNF-α) and 
interleukin 5 (IL-5), were higher in A/J compared to C3H/HeOuJ mice but did not reach 
significance. Thus, A/J mice showed an excessive release of pro-inflammatory cytokines that does 













Fig.17 Correlation of CFU with neutrophils in the BAL fluid  after P. aeruginosa infection in susceptible A/J and resistant C3H/HeOuJ mice. 
CFUs and neutrophils recovered in the BAL were plotted for the two murine strains during 18 hours of P. aeruginosa infection. Blue dots represent A/J 
mice (n= 12, for 6 and 12 hours, n= 9 for 18 hours ) and green dots C3H/HeOuJ mice ( n= 12 for each time). The data are pooled from two independent 
experiment. 
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 A/J         C3H/HeOuJ A/J vs C3H/HeOuJ 
Cytokines 6h 12h 18h 6h 12h 18h 6h 12h 18h 
 IL1α 777.405 443.0235 157.775 378.485 489.875 241.995 * ns * 
IL1β 
 
726.39 1151.41 393.915 462.985 492.23 302.1 ns ns ns 
IL2 
 
nd nd nd nd nd nd - - - 
IL3 
 
3.485 3.465 1.785 1.505 1.835 1.385 ns * ns 
IL-4 
 
15.595 13.555 12.085 9.675 12.67 10.725 ns ns ns 
IL5 
 
8.62 7.42 5.165 4.205 4.05 5.675 ns ns ns 
IL6 
 
473.33 378.19 193.035 305.56 201.27 176.795 ns * ns 
IL9 
 
35.7 36.43 48.495 35.705 35.7 55.195 ns ns ns 
IL10 
 
39.25 49.095 32.04 20.44 30.75 23.51 * * ns 
IL12p40 
 
56.4 21.655 23.855 14.59 19.8 21.21 * ns ns 
IL-12p70 
 
254.15 182.17 113.995 164.805 228.87 147.245 ns ns ns 
IL13 
 
71.26 74.4 73.515 40.14 55.46 65.09 * * ns 
IL17 
 
18.945 20.26 22.41 9.825 12.41 14.525 * * ns 
eotaxin 
 
nd nd nd nd nd nd - - - 
G CSF 
 
1778.86 5840.23 6713.8 607.365 2067.78 3266.77 * * ns 
GM CSF 
 
170.26 156.01 151.21 124.38 129.5 123.595 ns * ns 
IFNγ 
 
8.43 6.69 1.97 2.545 7.55 2.105 * ns ns 
KC 
 
68190 69190 69290 5793.96 6747.85 3068.26 * ns ns 
MCP1 
 
2826.25 1752.27 1109.07 757.01 1503.73 731.82 * ns ns 
MIP1α 
 
963.815 711.72 577.235 270.05 487.66 365.4 * ns ns 
MIP1β 
 
62.63 69.04 58.95 42.735 44.59 37.83 * ns ns 
RANTES 
 
32.67 45.24 27.125 15.22 25.115 34.03 ns ns ns 
TNFα 
 
18.08 15.105 16.6 9.76 12.38 15.105 ns ns ns 
          
Data are expressed as median of pg/500ug lung. 








Table 2. Cytokines and chemokines levels in lung homogenates of susceptible A/J and resistant C3H/HeOuJ mice infected with P. aeruginosa 
during a time course. Total lung homogenates protein content was quantified with Bradford’s assay at the final concentration of 500 mg/ml. A panel of 
23 chemokines and cytokines were meausered using Bio-Plex pro TM Mouse Cytokine Standard 23-Plex, Group I. Statistical analysis for comparison of A/J 
vs C3H/HeOuJ at each time point by the non-parametric Mann-Whitney U test (*p<0.05) is reported.  
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D4.2 Pathological differences in A/J and C3H/HeOuJ mice during acute pneumonia 
 
The histopathologic analysis of P. aeruginosa AA2–induced acute pneumonia revealed striking 
differences between A/J and C3H/HeOuJ mice (Fig. 18 and Fig. S4). During an early time course a 
fast and consistent recruitment of inflammatory cells in C3H/HeOuJ mice compared to a delayed 
and lower recruitment in A/J was observed (Fig. 18 A-C, E-G). More in detail, during early phases 
of infection pathologic scores showed that the high inflammatory response of C3H/HeOuJ resistant 
mice was characterized by strong polymorphonuclear leukocytes (PMNs) recruitment in BALF and 
in the interstitial areas of the lungs followed by a progressive increase in macrophages involvement 
and a moderate expansion of bronchus associated lymphoid tissue (BALT)-like structure (Fig. 18 
A-C, E-G and Fig. S4). These cell-mediated response may have a key role in mounting an effective 
response to control bacterial clearance. Indeed, immunofluorescence staining showed low number 
of P. aeruginosa cells in the lungs of C3H/HeOuJ mice (Fig. 18H). The susceptible A/J strain 
responded in a delayed manner characterized by a lower cell recruitment associated to low damage 
in the lung, and absence of a relevant interstitial/BALF response (Fig. 18 A-C, E-G and Fig. S4). 
The BALT-like structure observed in C3H/HeOuJ mice was substantially never observed in A/J 
susceptible strain. Indeed, immunofluorescence staining showed high numbers of P. aeruginosa 
cells localized both within the bronchial lumen and in the alveolar space indicating inadequate 





Figure 18 : Histopathology in susceptible A/J and resistant C3H/HeOuJ murine lungs after infection with P. aeruginosa. The lungs of A/J (A-D) 
and C3H/HeOuJ (E-H) were removed, fixed in 10% buffered formalin for at least 24 h and embedded in paraffin. Consecutive 2-µm sections from the 
middle of the five lung lobes were used for histological and immunofluorescence examination in each mouse. Sections for histological analysis were 
stained by Haematoxylin-Eosin according to standard procedures (A-C) and in immunofluorescence with specific antibody a rabbit anti serum specific for  
P. aeruginosa and Texas Red labelled goat anti- rabbit IgG as described (red)[51] (D, H). Counterstaining was performed with 49,6-Diamidino-2-
phenylindole dihydrochloride (DAPI) (blue). After time course analysis, extensive infection and inflammation were visible in murine lungs with major 
differences between A/J and C3H/HeOuJ. Bars, 200 µm for H&E images, 100µm for immunofluorescence images. Severity of lesions and lung 
involvement was scored as reported in Fig S4. Arrows indicate BALT-like structure in C3H/HeOuJ and A/J mice. 
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E. Conclusions and Future prospects 
 
E1. Identification and validation of novel Pseudomonas aeruginosa virulence 
factors  
P. aeruginosa  is an opportunistic Gram-negative human bacterium and one of the leading cause of 
hospital-acquired infections. This pathogen, displaying  a multifactorial and combinatorial virulence 
[33], causes a wide range of acute and chronic diseases in a large category of patients at risk 
including CF patients. It has been described that P. aeruginosa  acute infection is characterized by a 
large arsenal of virulence factors, such as flagella, type III secretion system, LPS and others. In 
contrast virulence factors required for the initiation of acute infections in CF are selected against 
during chronic infection leading to less invasive strains [50].  
Consistent with its large genome size and environmental adaptability, P. aeruginosa contains the 
highest proportion of regulatory genes observed for a bacterial genome which leads to large and 
complex phenotypic versatility. Although over the past two decades an enormous  progress has 
been made in the genome analyses  approach to  identify  and characterize virulence factors 
involved in P. aeruginosa  infection pathogenesis, only 6.7% of its genes has a function verified 
experimentally and still one third of its genome has no attributed homology to any previously 
reported sequence. Consequently, there is still a lot of information to be uncovered with regards to 
the mechanisms used by this organism to cause disease. Taking into account all these 
considerations, the first aim of my thesis was to identify novel P. aeruginosa virulence factors. We 
developed a new screening strategy combining an in vitro testing for reduced production of 
virulence factors and validation in a cascade of in vitro and in vivo models including airways cells, 
non-mammalian host models (C. elegans,  D. melanogaster) and mouse model. We identified a total 
of 404 independent pleiotropic mutants (attenuated in two or more virulence traits). All 404 mutants 
were screened for reduced virulence in the two non-mammalian infection models and 43 mutants 
attenuated in both C. elegans and D. melanogaster, were then tested for  their reduced cytotoxicity 
on A549 alveolar epithelial cells. Screening of these mutants in A549 alveolar epithelial cells 
identified  28 mutants attenuated in their cytotoxicity potential. Among these mutants 19 were 
found to be attenuated in invasion capacity and 20 in IL-8 cytokine release. The screening generated 
at the end a selection of  genes differentially attenuated in the multi-host system listed in a Genomic 
Target Database and grouped by a ranking score based on the phenotypic outcomes and 
bioinformatics analyses. A comparative protein sequence analysis was carried out against six 
sequenced genomes (PA14, LESB58, PA7, 2192, C3719 and PACS2) of highly pathogenic P. 
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aeruginosa and against E. coli K12 and B. cenocepacia J2315 in order to check the rate of 
conservation and homology to human of these virulence factors. Finally we selected mutants in 
pvdQ and crc as they were attenuated in all phenotypes, non-mammalian models and in vitro 
assays, the mutants in kdpB, bphO and PA2414 as they were attenuated in all models except for D. 
melanogaster model, PA4916 as it was attenuated in all models except for C. elegans models and 
finally PA5156 and PA3613 as they did not show attenuation in the non-mammalian host models 
but showed again different levels of attenuation in the other in vitro assays. Stable in frame deletion 
mutants were generated by recombination system and validated for their virulence in a mouse acute 
infection model. Five out of eight mutants ( pvdQ, crc, bphO, PA4916 and PA5156)  showed 
attenuated lethality in the mouse model 
Through our screening, we were able to isolate a large number of mutants with insertions in genes 
already demonstrated to be required for P. aeruginosa virulence in nematodes and mammals, 
including genes involved in antibiotic resistance, biofilm formation, virulence factors production, 
metabolism and quorum sensing regulation. Similar to the C. elegans screening of  PA14  
transposon mutants described by Feinbaum et al [112], we identified a number of genes that are 
involved in adaptation to environmental stress by playing a protective role. Those include a large 
number of metabolic genes involved in the generation and transport of precursor metabolites and 
energy (bphO and PA2414), genes involved in DNA synthesis and modification (smpB, pdxA, 
PA3867, PA3950 and PA4282), genes involved in the  catabolism regulation (catabolite repression 
control protein, crc) and quorum sensing (3-oxo-C12-homoserine lactone acylase, pvdQ). The 
identification of a number of mutants corresponding to biofilm formation (psl, mucP and pelG), 
type IV and VI secretion systems (xcpT, pilD and tssA1), and stress response (phoR, rpoS and parR) 
also illustrate their importance for survival of P. aeruginosa in a host environment with more 
stringent and harmful conditions. In addition, genes with hypothetical function (PA4916, PA5156 
and PA3613)  and genes playing a part in amino acid synthesis and metabolism were identified 
(pauB1 coding for a D-amino acid oxidase, hisD coding for a histidinol dehydrogenase, PA3139 
coding for a threonine-phosphate-decarboxylase).  
In the screening cascade we observed that two mutants out of the eight  (PA5156, PA3613) selected 
for their pleiotropic phenotypes were not attenuated in the disease models C. elegans and D. 
melanogaster. In addition, while we have found accordance between presence or absence of 
attenuation for some targets in C. elegans and in the murine model (kdpB, pvdQ,  bphO, crc, 
PA3613), PA2414 was attenuated in C. elegans but not in mice and PA4916 and PA5156 were 
attenuated in the mouse model of acute infection, but not in C. elegans. Other incongruities were 
observed between the results obtained in mice and those from other screenings. A study by Tan and 
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coworkers [113] identified, by screening of 2,400 TnphoA mutants, genes products corresponding 
to virulence factors. They demonstrate that these mutants were less pathogenic in nematodes, plants 
and mice with some differences in term of attenuation between the C. elegans and mouse models, as 
observed  for some mutants in our screening models. Our data indicate that identification of 
virulence genes carried out mainly in vitro and in non-mammalian host model does not imply that 
they are relevant for their pathogenesis in vivo. The use of non-mammalian infection models has 
several critical aspects, as the temperature for the cultivation of the nematode that affects the 
expression of certain virulence factors, the absence of the target organ and the lack of specific 
receptors or pathways. However, although mice are the first choice for understanding infectious 
diseases in human, screening a large amount of mutants in mouse models is unfeasible. For these 
reasons non-mammalian models remain useful surrogate hosts. In addition to being largely used to 
identify virulence factors, C. elegans has been exploited to study responses to infection also with 
other pathogen like Enterococci [114] and Staphilococcus aureus [115], as well as to compare the 
virulence of P. aeruginosa clinical isolates together with D. melanogaster and G. mellonella models 
[116]. Furthermore, pathways conserved in vertebrates characterize Drosophila response to 
pathogens, and mammalian and C. elegans innate immune defenses [117] [118].  
Taken together our results suggest that, using a genomic approach devised to screen the entire P. 
aeruginosa genome for novel virulence genes and a multifaceted approach based on a sequential 
cascade of models for the validation step, we were able to identified several novel virulence genes. 
These genes should be further investigated for their function and could represent interesting targets 
for an innovative anti-virulence approach to P. aeruginosa infections. Several studies [119] [120] 
[121] describe a novel therapeutic approach for infectious disease interfering with the ability of the 
bacteria to activate specific virulence traits that are needed to establish infection, without killing or 
inhibiting bacterial growth, or with the host-pathogen interaction.  By preventing the expression or 
activity of virulence traits, the bacteria might be less able to colonize the host and less pathogenic. 
Targeting bacterial virulence is attractive since it is specific toward pathogenic bacteria. In addition, 
as this strategy does not directly kill the bacteria, there is presumably less evolutionary pressure for 
the development of resistance than with traditional antibiotics. This inhibition could also allow the 
host immune system, including the normal microbiota, to prevent bacterial colonization or clear any 
established infection. Some concerns should be considered about anti-virulence therapy for P. 
aeruginosa infections. P. aeruginosa virulence is a highly complex, multifactorial process requiring 
the coordinated activity of many bacterial gene products which can be widely different depending 
on the infection is established. The idea of a core set of virulence factors common to all infection 
models is unlikely. The spectrum of virulence factors that play a role in a given host model depends 
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on a wide variety of factors including the characteristics of the site of infection, the type of the 
immune response and the phase of infection, and even host response. Virulence factors playing a 
role in distinct types of P. aeruginosa infection in humans could be different, implicating a great 
effort to personalize the treatment and thus posing a challenge for the development of new 
therapeutics.  
Another concern deals with the anti-virulence approach in CF chronic infection. It has been shown 
that long-term colonization of the CF host is maintained by P. aeruginosa patho-adaptive lineages, 
which are clonal with the initially acquired strain and carry phenotypic variants [50]. A number of 
genetic mechanisms are responsible for generating clonal variants in P. aeruginosa. Most CF strains 
consistently acquire common mutations in virulence genes including motility genes, quorum-
sensing regulator, the type-III secretion system, the multidrug-efflux pump and in mutator 
phenotypes [51] [75]. Interestingly, virulence factors required for the initiation of acute infections 
are selected against during chronic infection. As described by several studies [51] [27] [17], the 
shift from an opportunistic toward a lifelong persistent phenotype has a major impact in dampening 
the innate immune recognition and deteriorating the lung function in CF patients. This evolutionary 
scenario is similar to that of the genomes of other pathogens. Genetic loss-of-function mutations 
confer indeed enhanced fitness of the pathogen in a host-associated environment as shown for other 
pathogen [122] [123] [124].  
This raises the question whether anti-virulence therapy could favor P. aeruginosa fitness to the CF 
lung leading to chronic infections. One possibility could be to target virulence genes only during 
acute phases of P. aeruginosa infection in CF patients, aiming to the eradication by the host 
immune system or to target virulence genes highly conserved during the progression of CF lung 
disease. 
 
E.2 Host genetic background influences the response to P. aeruginosa infection 
 
An increasing number of papers reports that the host genetic background significantly modulates 
the outcome of infectious diseases highlighting that in most cases multiple complex genetic 
interactions may have a key role in controlling infection [125]. These findings reveal  that 
pathogens and their associated phenotypes are not the only determinants of the corresponding 
infectious diseases. In the case of P. aeruginosa opportunistic infection, much influence on disease 
outcome has been mainly  attributed  to different bacterial phenotypes rather than to host genetic 
background. In the second part of my work thesis we selected nine inbred murine strains 
characterized by a wealth of genetic and phenotypic diversity and representing in a discrete part the 
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numerous hallmarks of the human population [98]. We show that different inbred murine strains are 
highly variable in their response to acute airway infection. During a time course analysis, a wide-
range response to P. aeruginosa infection has been observed both in the survival rate and body 
weight change of different inbred murine strains. Most notably, deviant clinical phenotypes were 
observed being the A/J, 129S2/SvPasCRL and DBA/2J as the most susceptible while 
BALB/cAnNCrl and C3H/HeOuJ the most resistant mouse  strains. Other murine strains (BALB/cJ, 
BALB/cByJ, C57BL/6J and C57BL/6NCrl) were found be relatively resistant. Furthermore, we 
demonstrate no significant behavioral differences among distinct sub-strains of C57BL/6 from 
Jackson (C57BL/6J) or Charles River (C57BL/6NCrl). As reported in other studies, recent 
observations suggest that different variants of C57BL/6 mice are similar when monitored for acute 
mortality but have a different susceptibility to P. aeruginosa infection in terms of chronic 
persistence [51]. When distinct sub-strains of BALB/c from Jackson (BALBc/J and BALB/cByJ) or 
Charles River (BALB/cAnNCrl) were compared, we did not find  any obvious differences. In this 
context, it is interesting to note that the widely used CB57BL/6 mice were not the most susceptible 
compared with other inbred strains. CB57BL/6 is also the background of Cftr-ko mice and it is 
known that these mice do not mimic human CF lung disease as in humans [126]. Our results open 
the question whether other mouse genetic background may better recapitulate the pulmonary 
abnormalities of CF patients. 
Some of the inbred mouse strains used in this work were tested previously by others employing 
different model systems [106] [80]. Intraperitoneal P. aeruginosa infection of 16 different strains of 
inbred mice showed enhanced resistance for C3H mice and susceptibility for A.BY [106] [127]. 
Most strains, including DBA/2J, C57Bl6/J and BALB/c, used also in our work, showed no 
significant differences. In another work, 11 inbred mouse strains were compared using aerosol 
model of P. aeruginosa infection [128]. DBA/2 were the most susceptible while A/J, C3H/HeN, 
SWR/J and B10.D2/nSnJ were the most resistant when monitored for mortality. Using a chronic 
model of P. aeruginosa infection and evaluating mortality and bacterial load, a more restricted 
number of four inbred mouse strains were compared. BALB/c mice were found to be resistant, and 
DBA/2 mice were identified as the most susceptible strain while C57BL/6NHsd and A/JCr mice 
were found to be relatively susceptible [107]. Additional papers characterized inflammatory 
response directly comparing one resistant and one susceptible mice considering as resistant and 
susceptible BALB/c and C57BL/6 [109][110], BALB/c and DBA/2 [108], C3H/HeN and BALB/c 
respectively [129, 130]. Taken together our results and those of previous reports, it seems that a 
comprehensive classification of mouse inbred strains into categories according to their resistance or 
susceptibility is difficult to achieve As demonstrated for P. aeruginosa and  other pathogens, the 
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differences in the disease outcome may be affected by the site of infection [131]; [132]. In the 
above mentioned works, different routes of administration have been used for P. aeruginosa 
infection including intraperitoneal [127], aerosol [133] or intratracheal (this work). Other factors 
have also been shown to influence the disease phenotype and, by interference, susceptibility or 
resistance. The size of the inoculum and the strain of the pathogen used seem to be particularly 
important. Different P. aeruginosa bacterial strains have been used including laboratory PAO1 
[133] or clinical strains PA-103, Fisher type 4 [127], and AA2 in this work. These results reveal a 
previously unrevealed level of complexity and show that conclusions regarding disease 
susceptibility induced by P. aeruginosa infection may be highly dependent on the experimental 
model that is used. Based on this body of evidence, it seems that a comprehensive classification of 
mouse inbred strains into categories according to their resistance or susceptibility is difficult to 
achieve. 
Mouse inbred strains are the starting point from which to explore causal phenotype-genotype 
relationships, including the identification of cell-mediate immune response and gene mapping. In 
this work, the susceptible A/J mice and the resistant C3H/HeOuJ have been used to gain deeper 
insight into the cellular and molecular factors that may contribute to different disease pathogenesis. 
High bacterial replication and inadequate immune-response was observed for A/J mice suggesting 
that susceptible mice are inefficient to keep in check the bacterial infection. In other words, A/J 
mice do not mount a proper, early immune defence leading to a permissive environment for 
bacterial replication and spreading from the airways to other organs and ultimately to a fast disease 
progression. The lack of the inflammatory response in A/J mice may not be attributable to deficient 
cytokines or chemokines response, rather mice showed an excessive or uncontrolled release of pro-
inflammatory cytokines suggesting an ongoing cytokine storm. Previous studies have demonstrated 
that  A/J mice are known to carry a loss-of-function mutation at the C5 locus, which is implicated in 
mobilizing inflammatory cells, in particular neutrophils, critical for host defense against infection 
[134]. Although this deficiency has been widely demonstrated to account for the susceptibility of 
A/J mice to several pathogens, such as Candida albicans [135] and Mycobacterium tuberculosis 
[136], we hypothesize that the C5 deficiency might not be  completely responsible for P. 
aeruginosa susceptibility, since inbred strains deficient (A/J and DBA/2) or non-deficient for C5 
(129S2/SvPasCRL) are equally susceptible to P. aeruginosa infection In contrast to susceptible A/J 
mice, resistant C3H/HeOuJ mice mount a faster and consistent immune-response that is able to 
efficiently control bacterial replication. In more detail, C3H/HeOuJ mice exhibited a prompter 
recruitment of inflammatory cells, mainly PMN, to the site of infection than did mice of the A/J 
strain. A balanced level of cytokines or chemokines has been observed in C3H/HeOuJ mice. 
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Furthermore, after a strong PMNs response of C3H/HeOuJ resistant mice, a progressive increase in 
macrophages involvement and BALT-like structure activation was observed. This BALT-like 
structure activation, instead, was substantially never observed in A/J susceptible strain. These 
differences clearly indicates that, in this model of infection, the two mouse strains react differently 
in modulation of inflammatory response and probably in the way of the antigen presentation to the 
lymphocytes of BALT. These cells may play a role in mounting a cell-mediated response to 
determine effective control or bacterial clearance. 
Other papers on inbred mice analysed the inflammatory response in susceptible and resistant strains 
showing controversial results about the biological significance of the early inflammatory response 
in modulating the course and outcome of P. aeruginosa infection. In agreement with our results, 
Morissette and co-workers reported a rapid influx of polymorphonuclear cells (PMN),  which was 
shortly followed by an efficient clearance of bacteria in BALB/c resistant mice, while DBA/2 
susceptible mice had a delay in both the inflammatory response and the initiation of bacterial 
clearance [83, 108]However, other papers report an accumulation of inflammatory cells in 
susceptible rather than resistant mice. An exaggerated inflammatory response dominated by PMN 
correlates with susceptibility to infection in C57Bl/6 mice, whilst a modest inflammatory response 
dominated with macrophages correlated with resistance in BALB/c mice [110] [109]. Nevertheless, 
it should be expected that differences in the experimental model used (acute versus chronic) may 
affect several physiological parameters, adding complexity to the overall picture of the P. 
aeruginosa/host interaction.  
Taken together, our results showed that survival to P. aeruginosa infection is clearly affected by 
genetic background. Comparative analysis of the cell-mediated immunity to P. aeruginosa infection 
in resistant and susceptible strains has been used in determining the key players of a successful 
versus an unsuccessful response to infection. During this early phase of infection, a prompt 
inflammatory response in the airways  provides a biological advantage in creating a non-permissive 
environment for P. aeruginosa replication and restraining  the spread to other organs. Thus, we 
speculate that host genetic make-up may have a role in the reduction of cell-mediated immunity that 
could be critical in the control of P. aeruginosa infection.  
So far, we identified mouse strains presenting deviant clinical and immunological phenotypes 
which are suitable for genetic analyses. F2 mouse lines generated from A/J susceptible and 
C3H/HeOuJ resistant mouse strain are under evaluation to identify the genes controlling the host 
lung response to P. aeruginosa infection by Quantitative traits loci mapping. Identification of these 
genetic factors will provide insight into the key molecular processes that control host/pathogen 
interactions and might reveal novel targets for therapeutic interventions. 




As suggested by our results, the complexity of host- pathogen interaction is strongly dependent 
upon two principal factors: the pathogen with its multifactorial and combinatorial virulence, and the 
host with its specific genetic background. Actually, the availability of bacteria and mouse complete 
genome sequence lead to a major boost in our understanding of host-pathogen interaction. In 
addition, a combined genetic strategy, applied both to the pathogen (e.g. random transposon 
mutation) and to the host (forward genetic analysis of susceptibility to infection), will shed 
considerable light on bacterial and host key factors involved in this interaction, favouring new 
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Pseudomonas aeruginosa is a common cause of healthcare-associated infections including pneumonia, 
bloodstream, urinary tract, and surgical site infections. The clinical outcome of P. aeruginosa infections may 
be extremely variable among individuals at risk and patients affected by cystic fibrosis. However, risk factors 
for P. aeruginosa infection remain largely unknown. To identify and track the host factors influencing P. 
aeruginosa lung infections, inbred immunocompetent mouse strains were screened in a pneumonia model 
system. A/J, BALB/cJ, BALB/cAnNCrl, BALB/cByJ, C3H/HeOuJ, C57BL/6J, C57BL/6NCrl, DBA/2J, and 
129S2/SvPasCRL mice were infected with P. aeruginosa clinical strain and monitored for body weight and 
mortality up to seven days. The most deviant survival phenotypes were observed for A/J, 129S2/SvPasCRL 
and DBA/2J showing high susceptibility and BALB/cAnNCrl and C3H/HeOuJ showing more resistance to 
P. aeruginosa infection. Next, one of the most susceptible and resistant mouse strains were characterized for 
their deviant clinical and immunological phenotype by scoring bacterial count, cell-mediated immunity, 
cytokines and chemokines profile and lung pathology in an early time course. Susceptible A/J mice showed 
significantly higher bacterial burden, higher cytokines and chemokines levels but lower leukocyte 
recruitment, particularly neutrophils, when compared to C3H/HeOuJ resistant mice. Pathologic scores 
showed lower inflammatory severity, reduced intraluminal and interstitial inflammation extent, bronchial and 
parenchymal involvement and diminished alveolar damage in the lungs of A/J when compared to 
C3H/HeOuJ. Our findings indicate that during an early phase of infection a prompt inflammatory response in 
the airways set the conditions for a non-permissive environment to P. aeruginosa replication and lock the 
spread to other organs. Host gene(s) may have a role in the reduction of cell-mediated immunity playing a 
critical role in the control of P. aeruginosa infection. These results now provide a basis for mapping genomic 
regions underlying host susceptibility to P. aeruginosa infection. 
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INTRODUCTION  
P. aeruginosa is one of the major and dreaded source of infections responsible for causing millions of cases 
each year in the community and 10-15% of all healthcare associated infections, with more than 300,000 
cases annually in the EU, North US and Japan. Patients at risk of acquiring P. aeruginosa are particularly 
those hospitalized in intensive care units (ICU) who may develop ventilator-associated pneumonia (VAP) 
and sepsis [137]. In general, patients with a compromised immune system, due to immunosuppressive 
therapies or underlying diseases such as cancer, AIDS or the hereditary disease cystic fibrosis (CF), are at 
risk to develop P. aeruginosa infection.  
The clinical outcome of P. aeruginosa infections may be extremely variable among individuals at risk and 
CF patients. In particular, heterogeneity in the severity of chronic bronchopulmonary
 
P. aeruginosa infection 
is well documented in CF, while in other patients remains to be established [138]. According to clinical 
studies, the progression and severity of pulmonary disease in CF do not appear to correlate with the type of 
Cystic Fibrosis Transmembrane Regulator (CFTR) variant and rather seem to be largely dependent on 
secondary factors [139]. Much influence on disease outcome has been attributed more to different P. 
aeruginosa phenotypes rather than to host genetic background. Consistent with its larger genome size and 
environmental adaptability, P. aeruginosa contains the highest proportion of regulatory genes observed for a 
bacterial genome which lead to large and complex phenotypic versatility. Thus, early studies from different 
groups including ours [140-143] highlighted the responsibility of particular P. aeruginosa phenotypes for 
differential disease manifestations and pathogenesis. For instance, the shift from the opportunistic toward a 
life-long persistent phenotype has a major impact in dampening the innate immune recognition and 
deteriorating the lung function [144]. These studies somewhat neglected the potential importance of host 
factors. More recently, special interest has shifted toward understanding host genetic variation that alters the 
outcome of P. aeruginosa infection [145]. Identifying and tracking risk factors for P. aeruginosa infection 
remains one of the major research challenge.  
From studies of genetic predisposition in other infectious disease it has become clear that the host response is 
not only influenced by single genes but by combinations of genes and their variants [146, 147]. Thus, 
complex (multi-gene) genetic effects need to be analyzed to understand the full repertoire of host responses 
to pathogens. Several candidate gene association studies have been carried out in humans. However, 
although studies in humans are essential, they are limited because of the size of cohorts, strong but often 
unknown environmental influences, poor diagnosis, and lack of repeatability [145]. Therefore, animal 
models are absolutely essential to complement human studies.  
To meet the current challenge of deepening genetic susceptibility to infection and dissection of genetic traits 
analysis, well defined mouse genetic reference populations (GRP) have been a powerful force. Mouse GRP 
are available as inbred laboratory and wild-derived mouse strains, recombinant inbred strains, interspecific 
recombinant inbred strains, chromosome substitution strains, and consomic strains [148]. More than 200 
commercially available, phylogenetically diverse inbred mouse strains that contain enough genetic diversity 
to identify major differences in response to a specific infection are available [149]. These resources have 
  73 
been extensively used to identify cellular and molecular factors that may contribute to different disease 
pathogenesis and to analyze the effect of multiple contributing gene loci influencing disease phenotype with 
different pathogens [146, 150]. Successful stories included gene mapping for a large number of pathogens 
like bacteria (e.g. Salmonella enterica serovar Typhimurium, Mycobacterium bovis, Bacillus anthracis, 
Staphilococcus aureus and Legionella pneumophila), parasites (e.g. Plasmodium chabaudi, Candida 
albicans, and Leishmania donovani) and viruses (e.g Cytomegalovirus, Vescicular stomatitis virus and 
Orthomyxovirus) [149, 151]. Surprisingly, to our knowledge this approach has not been used to map for 
genetic determinant(s) of P. aeruginosa infection.   
As a first step toward the analysis of genetic traits influencing resistance and susceptibility to P. aeruginosa 
infection and the characterization of pathogenetic mechanims, we screened nine inbred mouse strains of 
differing ancestry and chosen for the known differences in their ability to overcome infections with various 
pathogens. Using characterized mouse model of acute infection with P. aeruginosa clinical strains and 
previous experience in this model system [152, 153], we identified mouse strains presenting deviant clinical 
and immunological phenotypes amenable for biological and genetic analyses.  
 
  74 
RESULTS  
Survival and body weight of P. aeruginosa-infected inbred mice is strongly dependent upon genetic 
background.  
Nine different inbred mouse strains, namely A/J, BALB/cJ, BALB/cAnNCrl, BALB/cByJ, C3H/HeOuJ, 




of planktonic P. 
aeruginosa clinical isolate AA2 via intra-tracheal injection, and monitored for change in body weight and 
mortality over a period of seven days. As shown in Fig. 1, a wide-range of survival and weight loss were 
observed among different inbred mice. The most deviant survival phenotypes were observed for A/J, 
129S2/SvPasCRL and DBA/2J showing high susceptibility and BALB/cAnNCrl and C3H/HeOuJ showing 
more resistance to P. aeruginosa infection. BALB/cJ, BALB/cByJ, C57BL/6J, C57BL/6NCrl showed 
intermediate phenotype. In more detail, susceptible A/J, 129S2/SvPasCRL and DBA/2J died within the first 
two days of infection, showed a mean survival time of around one day and a rapid and fatal decrease of body 
weight (Fig. 1A, B and C). Within the susceptible mice, A/J were significantly different compared to 
DBA/2J and 129S2/SvPasCRL showing a faster decrease of body weight at day one (Table S1) and a kinetic 
of death significantly more rapid (Fig. 1A). Resistant mice BALB/cAnNCrl and C3H/HeOuJ showed a 
significant lower susceptibility to P. aeruginosa infection compared with A/J, DBA/2J and 
129S2/SvPasCRL with cases of survival, a mean survival time of at least three days and a progressive weight 
recovery of the survivors at day seven (Fig. 1A, B and C). Within the resistant mice, BALB/cAnNCrl and 
C3H/HeOuJ were not significantly different for the body weight, kinetic of death and survival time (Table 
S1 and Fig. 1). The above described differences in resistance and susceptibility of most deviant inbred mice 




(Table S2 and Figure 
S1).  
 
Impaired cell-mediated immunity leads to faster replication of P. aeruginosa in A/J mice when 
compared to C3H/HeOuJ.  
Next, one of the most susceptible and resistant mouse strains were characterized for their deviant clinical and 
immunological phenotypes after P. aeruginosa AA2–induced acute pneumonia. The P. aeruginosa load and 
immune response of infected mice in terms of leukocyte recruitment, myeloperoxidase activity, and local 
cytokine production in the airways were investigated in A/J and C3H/HeOuJ mice during an early time 
course (6, 12 and 18 hours post-infection). Starting from a challenge of 5x10
6 
CFU, significant increase of 
total bacterial load up to 2 log10 CFU (4.1x10
8
) at 18 hours in the lung of susceptible A/J mice was observed 
indicating an uncontrolled replication of bacterial cells (Fig. 2A). Conversely at the same time points, the 
bacterial load in the lungs of resistant C3H/HeOuJ mice was unchanged in respect to the initial inoculum 
(6.9 x 10
6
) suggesting that resistant mice are able to keep in check the infection. A/J susceptible and 
C3H/HeOuJ resistant mice were significantly different in their bacterial load at all time points. Similar 
differences were also observed in different airways compartments as assessed by the Broncho Alveolar 
Lavage Fluid (BALF) (Fig. 2B) and lung homogenate analysis (Fig. 2C).  
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Leukocyte recruitment in the BALF of susceptible A/J mice early after P. aeruginosa infection was 
significantly lower than C3H/HeOuJ resistant mice (Fig. 2D). Furthermore, while the low leukocyte numbers 
remained stable in A/J during 18 hours, their recruitment in C3H/HeOuJ increased and reached the pick at 
12h. In particular, a significant increase in neutrophil levels for C3H/HeOuJ, compared to A/J was observed 
during 18h (Fig. 3A). The higher level of myeloperoxidase (MPO) activity in the BALF of C3H/HeOuJ 
compared to A/J supported these data (Fig. S2). Macrophages were also significantly higher in the lung of 
C3H/HeOuJ mice compared to A/J mice at 12 hours post infection, but no striking differences were present 
at 6 and 18 hours post infection (Fig. 3B). Lymphocytes and epithelial cells showed a trend being higher in 
C3H/HeOuJ mice but did not reach significance (Fig. 3C and D).  
When CFUs and neutrophils recovered in the BAL were plotted together, a distinct trend was observed in 
A/J and C3H/HeOuJ mice during 18 hours of infection. Fig 4 showed a lower number of neutrophils 
recruited and a higher number of P. aeruginosa CFUs in A/J mice in comparison to C3H/HeOuJ mice. In 
particular, looking at the ratio of  P. aeruginosa CFUs and neutrophils, significant differences were found 
(Fig S3). During the whole time-course, the ratio between CFUs and neutrophils was significantly lower for 
C3H/HeOuJ mice when compared to A/J mice, indicating a higher capacity of C3H/HeOuJ mice to control 
P. aeruginosa infection.  
 
A/J mice showed higher cytokines and chemokines profile in the airways when compared to 
C3H/HeOuJ mice during acute P. aeruginosa pneumonia. 
To better characterize the airway inflammatory response of the two deviant inbred mouse strains, we 
measured the concentration of a large panel of twenty-three cytokines and chemokines in murine lung 
homogenates. As shown in Table 1, the overall levels of pro-inflammatory cytokines were significantly 
higher in the lung of A/J mice respect to C3H/HeOuJ mice and reach significance for IL-17, G-CSF, GM-
CSF, IFN-γ, IL-6, IL-1α, KC, MCP1 and MP1 in at least one time point. Other cytokines, TNF-α and IL-5, 
were higher in A/J compared to C3H/HeOuJ mice but did not reach significance. Thus, A/J mice showed an 
excessive release of pro-inflammatory cytokines that does not correlate with cellular response when 
compared to C3H/HeOuJ mice.  
 
Pathological differences in A/J and C3H/HeOuJ mice during P. aeruginosa acute pneumonia. 
The histopathologic analysis of P. aeruginosa AA2–induced acute pneumonia revealed striking differences 
between A/J and C3H/HeOuJ mice (Fig. 5 and Fig. S4). During an early time course a fast and consistent 
recruitment of inflammatory cells in C3H/HeOuJ mice compared to a delayed and lower recruitment in A/J 
was observed (Fig. 5 A-C, E-G).  
More in detail, during early phases of infection pathologic scores showed that the high inflammatory 
response of C3H/HeOuJ resistant mice was characterized by strong polymorphonuclear leukocytes (PMNs) 
recruitment in BALF and in the interstitial areas of the lungs followed by a progressive increase in 
macrophages involvement and a moderate expansion of bronchus associated lymphoid tissue (BALT)-like 
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structure (Fig. 5 A-C, E-G and Fig. S4). These cell-mediated response may have a key role in mounting an 
effective response to control bacterial clearance. Indeed, immunofluorescence staining showed low number 
of P. aeruginosa cells in the lungs of C3H/HeOuJ mice (Fig. 5H).  
The susceptible A/J strain responded in a delayed manner characterized by a lower cell recruitment 
associated to low damage in the lung, and absence of a relevant interstitial/BALF response (Fig. 5 A-C, E-G 
and Fig. S4). The BALT-like structure observed in C3H/HeOuJ mice was substantially never observed in 
A/J susceptible strain. Indeed, immunofluorescence staining showed high numbers of P. aeruginosa cells 
localized both within the bronchial lumen and in the alveolar space indicating inadequate response of A/J 
mice to control bacterial replication in the lung (Fig. 5D).  
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DISCUSSION  
 
An increasing number of papers reports that the host genetic background significantly modulates the 
outcome of infectious diseases highlighting that in most cases multiple complex genetic interactions may 
have a key role in controlling infection [146]. These findings reveal that pathogens and their associated 
phenotypes are not the only determinants of the corresponding infectious diseases. In the case of P. 
aeruginosa opportunistic infection, much influence on disease outcome has been mainly attributed to 
different bacterial phenotypes rather than host genetic background. Here, we selected nine inbred murine 
strains characterized by a wealth of genetic and phenotypic diversity and representing a discrete part of the 
numerous hallmarks of the human population [149]. We show that different inbred murine strains are highly 
variable in their response to acute airway infection. During a time course analysis, a wide-range response to 
P. aeruginosa infection has been observed both in the survival rate and body weight change of different 
inbred murine strains. Most notably, deviant clinical phenotypes were observed being the A/J, 
129S2/SvPasCRL and DBA/2J as the most susceptible while BALB/cAnNCrl and C3H/HeOuJ the most 
resistant murine strains. Other murine strains (BALB/cJ, BALB/cByJ, C57BL/6J and C57BL/6NCrl) showed 
intermediate phenotype. Furthermore, we demonstrate no significant behavioral differences among distinct 
sub-strains of C57BL/6 from Jackson (C57BL/6J) or Charles River (C57BL/6 NCrl). As reported in other 
studies, recent observations suggest that different variants of C57BL/6 mice are similar when monitored for 
acute mortality but have a different susceptibility to P. aeruginosa infection in terms of chronic persistence 
[141]. When distinct sub-strains of BALB/c from Jackson (BALB/cJ and BALB/cByJ) or Charles River 
(BALB/cAnNCrl) were compared, we did not find any obvious differences. In this context, it is interesting to 
note that the widely used CB57BL/6 mice were not the most susceptible to P. aeruginosa infection compared 
to other inbred strains. C57BL/6 is also the background of Cftr-ko mice and it is known that these mice do 
not mimic human CF lung disease as in humans [152]. Our results open the question whether other mouse 
genetic background may better recapitulate the pulmonary abnormalities of CF patients during P. aeruginosa 
infection. 
Some of the inbred mouse strains used in this work were tested previously by others employing different 
model systems of P. aeruginosa infection. So far, three papers directly compared more than four inbred 
mouse strains [127, 133, 154]. Intraperitoneal P. aeruginosa infection of 16 different strains of inbred mice 
showed enhanced resistance for C3H mice and susceptibility for A.BY [127]. Most strains, including 
DBA/2J, C57BL/6J and BALB/c, used also in our work, showed no significant differences. In another work, 
11 inbred mouse strains were compared using aerosol model of P. aeruginosa infection [133]. DBA/2J were 
the most susceptible while A/J, C3H/HeN, SWR/J and B10.D2/nSnJ were the most resistant when monitored 
for mortality. Using a chronic model of P. aeruginosa infection and evaluating mortality and bacterial load, a 
more restricted number of four inbred mouse strains were compared. BALB/c mice were found to be 
resistant, and DBA/2J mice were identified as the most susceptible strain while C57BL/6NHsd and A/JCr 
mice were found to be relatively susceptible [154]. Additional papers characterized inflammatory response 
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directly comparing one resistant and one susceptible mice considering as resistant and susceptible BALB/c 
and C57BL/6 [155, 156], BALB/c and DBA/2 [157], C3H/HeN and BALB/c respectively [158, 159]. Taken 
together our results and those of previous reports, it seems that a comprehensive classification of mouse 
inbred strains into categories according to their resistance or susceptibility is difficult to achieve. As 
demonstrated for other pathogens, the differences in the disease outcome may be affected by the site of 
infection [160, 161]. In the above mentioned works, different routes of administration have been used for P. 
aeruginosa infection including intraperitoneal [127], aerosol [133] or intratracheal (this work and [154]). 
Other factors have also been shown to influence the disease phenotype and, by interference, susceptibility or 
resistance. The size of the inoculum and the strain of the pathogen used seem to be particularly important. 
Different P. aeruginosa bacterial strains have been used, including laboratory PAO1 [133] or clinical strains 
PA-103 [127], PA-508 [154] and AA2 in this work. These results suggest a previously unrevealed level of 
complexity and show that conclusions regarding disease susceptibility induced by P. aeruginosa infection 
may be highly dependent on the experimental model that is used.  
Mouse inbred strains are the starting point from which to explore causal phenotype-genotype relationships, 
including the identification of cell-mediate immune response and gene mapping. In this work, the susceptible 
A/J mice and the resistant C3H/HeOuJ have been used to gain deeper insight into the cellular and molecular 
factors that may contribute to different disease pathogenesis. High bacterial replication and inadequate 
immune-response was observed for A/J mice suggesting that susceptible mice are inefficient to keep in check 
the bacterial infection. In other words, A/J mice do not mount a proper, early immune defence leading to a 
permissive environment for bacterial replication and spreading from the airways to other organs and 
ultimately to a fast disease progression. The lack of the inflammatory response in A/J mice may not be 
attributable to deficient cytokines or chemokines response, rather mice showed an excessive or uncontrolled 
release of pro-inflammatory cytokines, suggesting an ongoing cytokine storm. Previous studies have 
demonstrated that  A/J mice are known to carry a loss-of-function mutation at the C5 locus, which is 
implicated in mobilizing inflammatory cells, in particular neutrophils, critical for host defense against 
infection [134]. This deficiency has been widely demonstrated to account for the susceptibility of A/J mice to 
several pathogens, such as Candida albicans [162] and Mycobacterium tuberculosis [163]. However, 
deficiency of C5 may not be completely responsible for P. aeruginosa susceptibility since inbred strains 
deficient (A/J and DBA/2) or non-deficient for C5 (129S2/SvPasCRL) are equally susceptible to P. 
aeruginosa infection. 
In contrast to susceptible A/J mice, resistant C3H/HeOuJ mice mount a faster and consistent immune-
response that is able to efficiently control bacterial replication. In more detail, C3H/HeOuJ mice exhibited a 
prompter recruitment of inflammatory cells, mainly PMN, to the site of infection than did mice of the A/J 
strain. A balanced level of cytokines or chemokines has been observed in C3H/HeOuJ mice. Furthermore, 
after a strong PMNs response of C3H/HeOuJ resistant mice, a progressive increase in macrophages 
involvement and BALT-like structure activation was observed. This BALT-like structure activation, instead, 
was substantially never observed in A/J susceptible strain. These differences clearly indicates that, in this 
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model of infection, the two mouse strains react differently in modulation of inflammatory response and 
probably in the way of the antigen presentation to the lymphocytes of BALT. These cells may play a role in 
mounting a cell-mediated response to determine effective control or bacterial clearance. 
Other papers on inbred mice analysed the inflammatory response in susceptible and resistant strains showing 
controversial results about the biological significance of the early inflammatory response in modulating the 
course and outcome of P. aeruginosa infection. In agreement with our results, Morissette and co-workers 
reported a rapid influx of PMN which was shortly followed by an efficient clearance of bacteria in BALB/c 
resistant mice, while DBA/2 susceptible mice had a delay in both the inflammatory response and the 
initiation of bacterial clearance [154, 157]. However, other papers report an accumulation of inflammatory 
cells in susceptible rather than resistant mice. An exaggerated inflammatory response dominated by PMNs 
correlates with susceptibility to infection in C57BL/6 mice, whilst a modest inflammatory response 
dominated with macrophages correlated with resistance in BALB/c mice [155, 156]. Nevertheless, it should 
be expected that differences in the experimental model used (acute vs chronic) may affect several 
physiological parameters, adding complexity to the overall picture of the P. aeruginosa/host interaction.  
Taken together, our results showed that survival to P. aeruginosa infection is clearly affected by genetic 
background. Comparative analysis of the cell-mediated immunity to P. aeruginosa infection in resistant and 
susceptible strain has been used in determining key player of a successful versus an unsuccessful response to 
infection. During this early phase of infection, a prompt inflammatory response in the airways provides a 
biological advantage in creating a non-permissive environment for P. aeruginosa replication and locking the 
spread to other organs. Thus, we speculate that host gene(s) may have a role in the reduction of cell-mediated 
immunity playing a critical part in the control of P. aeruginosa infection. With the use of recombinant inbred 
strategies, the survival differences between A/J and C3H/HeOuJ mice will permit future mapping of key 
genes involved in P. aeruginosa infection. 
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MATERIALS AND METHODS  
Ethic Statement.  
Animal studies were conducted according to protocols approved by San Raffaele Scientific Institute (Milan, 
Italy) Institutional Animal Care and Use Committee (IACUC) and adhered strictly to the Italian Ministry of 
Health guidelines for the use and care of experimental animals (Permit number: 502). Research on the 
bacterial isolates from the individual with CF has been approved by the responsible physician at the CF 
center at Hannover Medical School, Germany. Patient gave informed consent before the sample collection. 
Approval for storing of biological materials was obtained by the Hannover Medical School, Germany 
 
Bacterial strain.  
P. aeruginosa clinical isolate AA2 was obtained from a CF patient attending the Medizinische Hochschule 
of Hannover, Germany at the onset of chronic colonization and described before [141, 153]. The strain was 
cultured in trypticase soy broth (TSB) and plated on trypticase soy agar (TSA). 
 
Mouse model of P. aeruginosa acute infection. 
Nine inbred immune-competent mouse strains eight weeks old namely A/J, BALB/cJ, BALB/cByJ, 
C3H/HeOuJ, C57BL/6J and DBA/2J were purchased from Jackson (J) and BALB/cAnNCrl, C57BL/6NCrl, 







of planktonic P. aeruginosa clinical isolate AA2 according with established procedures [153]. 
Briefly, mice were anesthetized  by an intra-peritoneal injection of a solution of 2.5% Avertin (2,2,2-
tribromethanol, 97%; Sigma Aldrich) administered in a volume of 0.015 mlg
-1
 body weight and the trachea 
directly visualized by a ventral midline incision, exposed and intubated with a sterile, flexible 22-g cannula 




CFU were implanted via the cannula into the 
lung, with both lobes inoculated. After infection, mortality and body weight were monitored over one week. 
Animals showing more than 25% of body weight loss were euthanized and documented as dead. For the time 
course, additional groups of mice were sacrificed by CO2 administration at 6, 12 and 18 hours and analysed 
for CFU in the lung, BALF cell count and myeloperoxidase (MPO) activity as previously described [164, 
165]. In another group of mice, the lungs were excised and used for histopathology.  
 
BALF and lung collection and analysis.  
BALF was extracted with a 22-gauge venous catheter by washing the lungs with RPMI-1640 (Euroclone) 
with protease inhibitors (Complete tablets, Roche Diagnostic and PMSF, Sigma) [166]. Total cells present in 
the BALF were counted, and a differential cell count was performed on cytospins stained with Diff Quick 
(Dade, Biomap, Italy). BALF was serially diluted and plated on TSB-agar plates. After erythrocyte lysis with 
ACK lysis solution (pH 7.2; NH4Cl 0.15 M, KHCO3 10 mM, EDTA 0.1 mM), cells were resuspended in 
cetyltrimethylammonium chloride 0.5% (Sigma Aldrich) and centrifuged. The clear extracts were used to 
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analyse the MPO activity: samples were mixed with equal volumes of 3,3′,5,5′-tetramethyl-benzidine 
dihydrochloride for 2 min and the reaction stopped by adding H2SO4. The OD was measured at 450 nm. 
 
Lung homogenization and cytokine analysis.  
Lungs were removed and homogenized in PBS with Ca2+/Mg2+ containing protease inhibitors. Samples 
were serially diluted and plated on the above agar media for CFU counts. Lung homogenates were then 
centrifuged at 14,000 rpm for 30 minutes at 4°C, and the supernatants were stored at – 20°C for cytokine 
analysis. 
 Total lung homogenates  protein content was quantified with Bradford’s assay (Bio-RAD) at the final 
concentration of 500µg /ml. A panel of 23 murine chemokines and cytokines were measured using Bio-Plex 
pro
TM
 Mouse Cytokine Standard 23-Plex, Group I according to the manufacterer’s instructions. 
 
Histologic and immunofluorescence analysis. 
Lungs were removed, fixed in 10% buffered formalin for at least 24 h and embedded in paraffin. 
Consecutive 2-mm sections from the middle of the five lung lobes were used for histological and 
immunofluorescence examination in each mouse. Sections for histological analysis were stained by 
Haematoxylin-Eosin according to standard procedures. To grade inflammation severity and extent (e.g 
diffuse, intraluminal and/or interstitial), alveolar damage, bronchial involvement, and percentage of 
parenchyma involved histological score analysis of murine lungs was performed as described in the 
Supplementary Materials. 
Localization of  P. aeruginosa was performed in de-paraffinized lung sections by employing a rabbit 
antiserum specific for P. aeruginosa and Texas Red-labelled goat anti-rabbit IgG as described [141]. The 
slides were examined using an Axioplan fluorescence microscope (Zeiss) and images were taken with a KS 
300 imaging (Kontron). 
 
Statistical analysis.  
Results are presented as median or mean ±SEM. Because of the small sample size and the non-normal 
distribution of variables, we used a nonparametric approach for most part  of analysis. The Mann –Whitney 
U test was used to compare CFU, cells, MPO activity, cytokines levels and histologic measurements between 
A/J and C3H/HeOuJ mice. Mantel–Cox test was used to determine the significance of differences in means 
between pairs. Two- way ANOVA with Bonferroni’s Multiple Comparison test was used to compare change 
in body weight. One-way ANOVA with  Bonferroni’s Multiple Comparison test was used to compare the 
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TABLE 
Table 1. Cytokines and chemokines levels in lung homogenates of susceptible A/J and resistant 
C3H/HeOuJ mice infected with P. aeruginosa during a time course.  
 A/J C3H/HeOuJ A/J vs C3H/HeOuJ 
Cytokines 6h 12h 18h 6h 12h 18h 6h 12h 18h 
IL1α 777.405 443.0235 157.775 378.485 489.875 241.995 * ns * 
IL1β 
 
726.39 1151.41 393.915 462.985 492.23 302.1 Ns ns Ns 
IL2 
 
nd nd nd nd nd nd - - - 
IL3 
 
3.485 3.465 1.785 1.505 1.835 1.385 Ns * Ns 
IL-4 
 
15.595 13.555 12.085 9.675 12.67 10.725 Ns ns Ns 
IL5 
 
8.62 7.42 5.165 4.205 4.05 5.675 Ns ns Ns 
IL6 
 
473.33 378.19 193.035 305.56 201.27 176.795 Ns * Ns 
IL9 
 
35.7 36.43 48.495 35.705 35.7 55.195 Ns ns Ns 
IL10 
 
39.25 49.095 32.04 20.44 30.75 23.51 * * Ns 
IL12p40 
 
56.4 21.655 23.855 14.59 19.8 21.21 * ns Ns 
IL-12p70 
 
254.15 182.17 113.995 164.805 228.87 147.245 Ns ns Ns 
IL13 
 
71.26 74.4 73.515 40.14 55.46 65.09 * * Ns 
IL17 
 
18.945 20.26 22.41 9.825 12.41 14.525 * * Ns 
eotaxin 
 
nd nd nd nd nd nd - - - 
G CSF 
 
1778.86 5840.23 6713.8 607.365 2067.78 3266.77 * * Ns 
GM CSF 
 
170.26 156.01 151.21 124.38 129.5 123.595 Ns * Ns 
IFNγ 
 
8.43 6.69 1.97 2.545 7.55 2.105 * ns Ns 
KC 
 
68190 69190 69290 5793.96 6747.85 3068.26 * ns Ns 
MCP1 
 
2826.25 1752.27 1109.07 757.01 1503.73 731.82 * ns Ns 
MIP1α 
 
963.815 711.72 577.235 270.05 487.66 365.4 * ns Ns 
MIP1β 
 
62.63 69.04 58.95 42.735 44.59 37.83 * ns Ns 
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RANTES 
 
32.67 45.24 27.125 15.22 25.115 34.03 Ns ns Ns 
TNFα 
 
18.08 15.105 16.6 9.76 12.38 15.105 Ns ns Ns 
          
 
Data are expressed as median of pg/500ug lung. 
Statistical analysis for comparison of A/J vs C3H/HeOuJ at each time point by the non-parametric Mann-
Whitney U test (*p<0.05) is reported.  
Nd: not detectable; ns: not significant.




Figure 1: Survival, body weight and mean survival time after P. aeruginosa infection in inbred mouse 
strains.  
A/J (n=22), BALB/cJ (n=9), BALB/cAnNCrl (n=8), BALB/cByJ (n=12), C3H/HeOuJ (n=26), C57BL/6J 
(n=10), C57BL/6NCrl (n=15), DBA/2J (n=12), and 129S2/SvPasCRL (n=12) mice were inoculated with 
5x10
6 
CFU of P. aeruginosa clinical isolate AA2, and monitored for survival (A) and weight change for a 
period of seven days after infection (C). In addition, mean survival time was calculated based on the survival 
curve (B). The data are pooled from two to four independent experiments. Statistical significance by Mantel-
Cox test for survival (A), One- way ANOVA with Bonferroni’s Multiple comparison test (B) for mean 
survival time (*p<0.05, **p<0.01, ***p<0.001). Statistical significance by  Two-way ANOVA with  
Bonferroni’ s Multiple comparison test  for body weight is reported in Table S1. 
 
Figure 2: P. aeruginosa load and leukocytes recruitment in BALF and lung of A/J and C3H/HeOuJ 
mice.  
A/J (n=12, for each time) and C3H/HeOuJ (n=12, for each time) mice were challenged with 5x10
6
 CFU of 
AA2 clinical stain and analysed during a time course post-infection. Bacterial loads in the total lung (A) 
including BAL (B) and lung homogenate (C) were counted at 6, 12 and 18 hours in surviving mice. Dots 
represent CFU per lung in individual mice and horizontal lines represent median values reported in log scale. 
Total leukocytes were analyzed in BALF of P. aeruginosa infected mice (D). Bars represent median values. 
Blue is referred to A/J and green to C3H/HeOuJ. The data are pooled from two independent experiments. 
Statistical significance by Mann-Whitney U test is indicated: **p<0.01, ***p<0.001,  ****p<0.0001. 
 
Figure 3: Lung inflammatory response in susceptible A/J and resistant C3H/HeOuJ P. aeruginosa-
infected mice. 
The number of neutrophils (A), macrophages (B), lymphocytes (C) and epithelial cells (D) recruited in the 
airways were determined in the BALF from A/J (n=12) (blue bar) and C3H/HeOuJ (n=12) (green bar) mice 
after 6, 12 and 18 hours of P. aeruginosa infection with 5x10
6 
CFU of AA2 clinical isolate. The data are 
pooled from two independent experiments. Statistical significance by Mann-Whitney U test is indicated: 
*p<0.05, **p<0.01, ***p<0.001.  
 
Figure 4: Correlation of CFU/neutrophils in the BAL of susceptible A/J and resistant C3H/HeOuJ P. 
aeruginosa-infected mice. 
CFUs and neutrophils recovered in the BAL were plotted for the two murine strains during 18 hours of P. 
aeruginosa infection. Blue dots represent A/J mice (n= 12, for 6 and 12 hours, n= 9 for 18 hours ) and green 
dots C3H/HeOuJ mice ( n= 12 for each time). The data are pooled from two independent experiment. 
 
Figure 5: Histopathology in susceptible A/J and resistant C3H/HeOuJ P. aeruginosa-infected mice.  
The lungs of A/J (A-D) and C3H/HeOuJ (E-H) were stained with H&E (A-C) and in immunofluorescence 
with specific antibody against P. aeruginosa (red) (D, H). Counterstaining was performed with 49,6-
Diamidino-2-phenylindole dihydrochloride (DAPI) (blue). After time course analysis, extensive infection 
and inflammation were visible in murine lungs with major differences between A/J and C3H/HeOuJ. Arrows 
indicate BALT-like structure. Bars, 200 µm for H&E images, 100µm for immunofluorescence images. 
Severity of lesions and lung involvement was scored as reported in Fig S4. 
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Supplementary materials 
MATERIALS AND METHODS  
Histologic analysis. 
To grade inflammation severity and extent (e.g diffuse, intraluminal and/or interstitial), alveolar damage, 
bronchial involvement, and percentage of parenchyma involved histological score analysis of murine lungs 
was performed. Histological examination primarily included the assessment of inflammation by scoring the 
number of inflammatory cells (mononuclear cells, such as macrophages, lymphocytes, and plasma cells, and 
neutrophils) at a magnification of 400. The number of inflammatory cells was evaluated by using a visual 
analogue scale modified for murine pulmonary specimens, as described previously {Cersini, 2003 #803}, 
and results are reported as the mean for the entire specimen. When considerable variation of intensity of 
infiltration was evident in the same specimen, the mean for several areas was determined and the specimen 
was scored accordingly. Neutrophils and mononuclear cells were classified as absent (score of 0) when there 
were no or fewer than 19 cells per high-power field (HPF) (at a magnification of 400), mild (score of 1) for 
20 to 49 cells per HPF, moderate (score of 2) for 50 to 99 cells per HPF, marked or severe (score of 3) for 
100 to 200 cells or more per HPF. Percent of parenchyma involved was scored as 0 when no area of the two 
lungs was interested. Considering 100 the entire area of the two lung sections performed in the sagittal 
direction, the involvement of the parenchyma was scored as 1 when approximately the 25% of the total area 
was occupied by inflammatory exudate; was scored as 2 when the involved area was comprised between 26 
to 50%, 3 if comprised between 51 to 75%, and 4 if between 76 to 100%. 
Histological criteria for normal pulmonary characteristics included detection of no or only a few 
mononuclear cells per HPF and no or only a few scattered neutrophils in bronchioli and alveoli without 
tissue changes (no interstitial thickening or bronchiolar-associated lymphoid tissue [BALT] activation and 
airways free from exudate). 
 




Figure S1: Survival, body weight and mean survival time after P. aeruginosa infection in inbred mouse 
strains. 
A/J (n=19), BALB/cAnNCrl (n=8), C3H/HeOuJ (n=17), C57BL/6NCrl (n=15) and 129S2/SvPasCRL (n=8) 
mice were inoculated with 5x10
5 
CFU of P. aeruginosa clinical isolate AA2, and monitored for survival (A) 
and weight change for a period of seven days after infection (C). In addition, mean survival time was 
calculated based on the survival curve (B). The data are pooled from two to three independent experiments. 
Statistical significance by Mantel-Cox test for survival (A), One- way ANOVA with Bonferroni’s Multiple 
comparison test (B) for mean survival time (*p<0.05, **p<0.01, ***p<0.001). Statistical significance by 
Two-way ANOVA with Bonferroni’s Multiple comparison  test for body weight is reported in Table S1B. 
 
Figure S2: Myeloperoxidase activity in susceptible A/J and resistant C3H/HeOuJ P. aeruginosa-
infected mice. MPO activity was measured in the BALF of A/J (n= 12) and C3H/HeOuJ (n= 12) mice after 
6, 12 and 18 hours of infection with 5 x10
6
 CFU of AA2 clinical isolate. The data are pooled from two 
independent experiments. Statistical significance by Mann- Whitney U test is indicated: ***p<0.001 
 
Figure S3: Ratio CFU /neutrophils in the BALF of susceptible A/J and resistant C3H/HeOuJ P. 
aeruginosa-infected mice. A/J (n=12 for 6 and 12 hours, n=9 for 18 hours) and C3H/HeOuJ (n= 12 for each 
time) showed a significant different ratio of CFU /neutrophils in the BALF during the whole time-course of 
infection. Dots represent the CFU /neutrophils ratio in individual mice and horizontal lines represent median 
values. The data are pooled from two independent experiments. Statistical significance by Mann-Whitney U 
test is indicated: *p<0.05, ***p<0.001,  ****p<0.0001. 
 
Figure S4: Histopathology in susceptible A/J and resistant C3H/HeOuJ P. aeruginosa-infected mice. 
Histological score analysis of A/J and C3H/HeOuJ lungs was performed at 6, 12 and 18 hours evaluating the 
degree of inflammation severity (A), inflammation extent–diffuse intraluminal (B), inflammation extent-
interstitial (C), alveolar damage (D), bronchial involvement (E), percentage of parenchyma involvement (F). 
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Table S1. Statistical comparison of change in body weight between inbred mice infected with 
5x10
6
 P. aeruginosa.  
 
 
Two way ANOVA test was used for pair wise comparisons between inbred mouse strains at different days (*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, ns not significant). Table reports only days in which significance between 
inbred mice has been observed.  
 
 
Table S2. Statistical comparison of change in body weight between inbred mice infected with 
5x10
5
 P. aeruginosa.  
 
Two way ANOVA test was used for pair wise comparisons between inbred mouse strains at different days (*p<0.05, 
**p<0.01, ***p<0.001, , ns not significant). Table reports only days in which significance between inbred mice has 
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Abstract 
P. aeruginosa remains a major burden in cystic fibrosis, wounds and nosocomial infections due to its high 
levels of intrinsic and acquired resistance to antibiotics. There is still one third of its genome with no 
attributed homology to any previously reported sequences with only 6.7% of its genes having a function 
verified experimentally. Consequently, there is still a lot of information to be uncovered with regards to the 
mechanisms used by this organism to cause disease with an array of novel antimicrobial targets remaining 
to be discovered within its genome.  
In order to identify novel targets for the treatment and prevention of diseases caused by this bacterium, we 
have used a genomic approach devised to screen the entire genome of P. aeruginosa for novel genes 
involved in virulence. Using Tn5 mutagenesis, we have generated a total of 57,360 mutants in P. aeruginosa 
PAO1-L strain.  The target screening was performed at different sequential levels. Firstly, mutants were 
individually tested for reduced swarming as well as pyocyanin and protease production. Then, a selection of 
those having pleiotropic phenotypes were further examined for attenuation in Caenorhabditis elegans, 
Drosophila melanogaster and, after a further shortlisting, for reduced cytotoxicity on respiratory cell lines. 
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Finally a total of 8 mutants resulting from these sequential screenings and the selection of genes not 
attenuated in virulence as controls were verified as potential virulence targets using a combination of a 
mouse acute infection model, together with cell invasion assays and IL-8 release employing the A549 
broncheo-epithelial cell assay. Although the role of some of these genes in the biology of P. aeruginosa has 
already been described (pvdQ, crc, kdpB and bphO) some of the other open reading frames identified 
correspond to genes with unknown function (PA2414, PA3613, PA4916 and PA5156).  Therefore, this study 
describes a screening strategy for the identification of novel genes impacting on the virulence of P. 
aeruginosa, which are highly conserved across genomes from Pseudomonas spp. and which can be further 
exploited as novel antimicrobial targets against infections caused by this opportunistic pathogen. This 
approach has several advantages including expanding the repertoire of bacterial targets, preserving the 
endogenous microbiota, and applying lower selective pressure, which could result in reduced resistance. 
 
Introduction 
Pseudomonas aeruginosa is common throughout the environment and remains one of the most commonly 
isolated nosocomial pathogen due to its high levels of intrinsic and acquired resistance to antibiotics 
(Govan and Deretic, 1996). P. aeruginosa colonises a large variety of anatomical sites causing a wide range 
of diseases in humans at various body sites, including the urinary tract, lungs, and burn wounds. Acute P. 
aeruginosa infection in immuno-compromised patients or chronic persistent lung infection in patients with 
cystic fibrosis (CF) are different at the cellular and organ levels and thus may require distinct treatments. 
Despite growing evidence about the severity of the diseases caused by P. aeruginosa, no drugs with a novel 
mechanism of action have been introduced. Although extensively investigated in many other pathogens 
(Shoop et al., 2005; Turk et al., 2004; Kauppi et al., 2003; Hung et al., 2005; Lyon et al., 2002; Mayville et al., 
1999; Wright et al., 2005; Svenson et al., 2001), virulence genes may represent targets for antibiotic 
discovery that are being explored only recently in P. aeruginosa (Baer M et al, Infect. Immun. 2009; Lazar H 
et al, Antimicrob. Agents Chemother. 2009).  
Although there has been a number of genome-wide screening studies to identify P. aeruginosa resistance 
genes and virulence factors (Wei et al., 2011; Dötsch et al., 2009; Feinbaum et al., 2012), the degree to 
which results of the P. aeruginosa virulence screening strategies are shared between multiple hosts 
remains unclear. A pathogen can experience several radically different “host environments” at various 
stages of infection (acute or chronic). P. aeruginosa is indeed capable of adapting to a wide range of 
environments and utilizes a broad spectrum of virulence determinants to infect various hosts from plants 
and insects to humans (Lyczak et al., 2000; Lyczak et al., 2002). Multiple virulence factors of P. aeruginosa 
include elastase, alkaline protease, exotoxin A, rhamnolipids, pyocyanin, the siderophore pyoverdin, lectins, 
and biofilm formation (Smith and Iglewski, 2003). The blue pigment pyocyanin, a redox-active phenazine 
compound that kills mammalian and bacterial cells through the generation of reactive oxygen 
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intermediates, is regulated through multifactorial mechanisms and hence alteration in pyocyanin 
production is likely to affect also other virulence determinants (Reimmann et al., 1997; Heurlier et al., 
2004). In addition, swarming plays a key role in virulence and is controlled by several regulatory networks 
such as the rhl and rsm systems, which also impact on virulence (Heurlier et al., 2004). In P. aeruginosa, 
cell-cell communication (known as Quorum sensing (QS)) is responsible for orchestrating the coordinated 
production of these virulence factors and promote biofilm maturation (Juhas et al., 2005; Williams et al., 
2007). The P. aeruginosa QS system consist of 2 N-acyl-homoserine lactone (AHL) regulatory circuits (las 
and rhl) linked to an alkyl-quinolone (AQ) QS system. LasR and RhlR are both LuxR transcriptional activators, 
which activity depends on AHLs synthesized via LasI and RhlI, respectively, to drive virulence gene 
expression. In various infection models, mutants defective in QS are significantly less pathogenic than their 
parental strains suggesting that QS systems may be an interesting target for the prevention of the acute 
and chronic P. aeruginosa infections (Pearson et al., 2000).  
P. aeruginosa possess a 6.3 Mb genome with 32% of its ORFs having no homology to any previously 
reported sequences. Furthermore, function of only 6.7% of the P. aeruginosa genes has been demonstrated 
experimentally (www.pseudomonas.com). The rest of the P. aeruginosa genome has been assigned 
predicted functions, based on homologies to previously characterised genes which remain to be 
demonstrated. This shows that there is still a large amount of information to be uncovered with regard to 
mechanisms used by this organism to cause disease, and, an array of antimicrobial targets remains to be 
discovered within it. In addition, given the intrinsic antimicrobial resistance of P. aeruginosa and the need 
for alternative therapies, there is the possibility that many new targets for novel antimicrobials have yet to 
be identified.   
In order to identify new targets for the treatment and prevention of diseases caused by this bacterium we 
have used a genomic approach devised to screen the entire P. aeruginosa genome for novel virulence 
genes. Using Tn5 mutagenesis, we have generated a total of 57,360 mutants for PAO1-L. Each mutant was 
tested for reduced swarming, exo-protease, and pyocyanin production. The selected genes were further 
validated for reduced toxicity, in a sequential cascade of disease models, including airways cell lines, D. 





Mice studies were conducted according to protocols approved by the San Raffaele Scientific Institute 
(Milan, Italy) Institutional Animal Care and Use Committee (IACUC) and adhered strictly to the Italian 
Ministry of Health guidelines for the use and care of experimental animals. 
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Bacterial strains, growth conditions, plasmids and general DNA manipulation 
The bacterial strains and plasmids used are listed in Table 1S. Escherichia coli and Pseudomonas aeruginosa 
were routinely cultured in Luria Bertani (LB) at 37oC under vigorous shaking (200 rpm). Media were 
solidified with 1.8% agar (Bacto agar; Difco). The antibiotics were added when required, to final 
concentrations for tetracycline of 125 µg/ml for P. aeruginosa and 10 µg/ml for E. coli, and for gentamicin, 
nalidixic acid, and streptomycin of 20 µg/ml, 15 µg/ml and 500 µg/ml for P. aeruginosa and E. coli, 
respectively.    
Genomic DNA isolation was performed using a Wizard Genomic DNA purification kit (Promega). Plasmid 
DNA isolation was performed using a Qiagen Midi Kit (Qiagen). All other DNA manipulation techniques 
including analysis, digestion, ligation and introduction of DNA into host cells by electroporation were 
performed as described by Sambrook and Russel (2001). 
 
Transposon mutagenesis 
Transposon mutants were generated by mating P. aeruginosa PAO1 obtained from D. Haas (Department of 
Microbiology, University of Lausanne, Switzerland) (referred to as PAO1-L) (Holloway collection) with E. coli 
strain λpir S17.1 carrying pLM1 derived from pRL27 (Larsen et al., 2002). P. aeruginosa mutants were 
selected by plating on LB agar containing gentamycin (20 µg/ml), streptomycin (500 µg/ml), and nalidixic 
acid (15 µg/ml). After incubation at 37oC for 16h mutant colonies were picked using a Flexis (Genomics 
Solutions, Huntingdon, Cambridgeshire, U.K.) colony-picking robot. Colonies were arrayed into 94-well 
plates containing 200 µl of 15% glycerol in LB. The microtitre plates were sealed using a gas-permeable 
membrane (Corning, Gillingham, Dorset, U.K.), incubated at 37oC for 16h and then stored at - 80oC. 
Mutant selection 
The P. aeruginosa mutant strains were screened for alterations in pyocyanin production, swarming motility 
and/or alkaline protease activity by visual examination with the aid of the colony picker described in the 
previous section which was programmed to replicate the bacterial cultures from 96-well plates into Omni 
Trays (Fisher Scientific, Loughborough, Leicestershire, U.K.) containing various solidified media: LB to assess 
pyocyanin production, swarming agar, or LB containing 5% (w/v) of skimmed milk for determination of 
protease activity.  
 
Transposon insertion location 
To determine the transposon insertion point in the chromosome of the selected Tn5 mutants, total 
genomic DNA was isolated and digested with EcoRI, which does not cut pLM1. Digested genomic DNA 
fragments were recircularised and, upon electroporation in E. coli λpir S17.1, selected for gentamicin 
resistance. DNA insert regions flanking the Tn5 were sequenced using primers tpnRL17-1 (5’-
AACAAGCCAGGGATGTAACG-3’) and tpnRL17-2 (5’-CAGCAACACCTTCTTCACGA-3’), at the Biopolymer 
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synthesis and analysis department, Queens Medical Centre, Nottingham, U.K.  DNA sequence analysis was 
performed using software packages provided by the National Centre for Biotechnology Information BLAST 
network server.   
        
C. elegans and D. melanogaster virulence assays 
To investigate the level of virulence attenuation of the selected mutants C. elegans and D. melanogaster 
disease models were employed. For the former, the C. elegans strain DH26 was used in slow killing assays. 
Worms were synchronized into L4 larval stadium by egg preparation, which was followed by incubation of 
isolated eggs on E. coli OP50 feeding plates at 20°C for around 76 hours.  Subsequently, L4 larvae were 
transferred onto lawns of the P. aeruginosa mutant strains grown in the 6-well plates (approximately 30 
worms per well) and incubated at 25°C. The surviving worms were counted after 24, 48 and 72 hours with 
the aid of a Stereolupe Stemi SV 6 (Zeiss, Goettingen, Germany). 
The pathogenicity of the mutants was determined from the survival rates of C. elegans in three 
independent replicates.  The D. melanogaster disease model was used as previously described (Apidianakis 
& Rahme, 2009). D. melanogaster Canton-S wild type flies were bred on standard cornmeal sucrose 
medium at room temperature. 2-9 days old male and female flies were used as infection hosts. Bacterial 
strains were grown in LB to an OD600 of 1.0. The cells were harvest, washed and adjusted with 10 mM 
MgSO4 to an OD600 of 2.0. Flies were anaesthetized with ether and bacterial suspensions were inoculated 
into the thorax using a tungsten needle. For each trial, triplicate sets of 15 flies were used and the 
experiment was performed in duplicate. The negative control flies were inoculated with a 10 mM MgSO4 
solution. If more than 5 flies died because of injury caused during pricking, the experiment was repeated. 
The pricked flies were incubated at 26°C and counted every hour between 11h to 22h post infection.    
    
In silico analysis  
Comparative protein sequence analysis was carried out against the six sequenced genomes (PA14, LESB58, 
PA7, 2192, C3719 and PACS2) of P. aeruginosa and against E.coli K12 and B. cenocepacia J2315 in order to 
check presence and conservation of our candidates in other P. aeruginosa genomes and in other bacterial 
species. The BLASTP program, present on the NCBI website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins), was used for homology analysis. Analysis was done 
by aligning the amino acid sequence of PAO1 against other genomes.Genes identified in our screen 
were then checked for presence in the set of virulence-related genes annotated in the 
Virulence Factor Database (VFDB) (http://www.mgc.ac.cn/VFs/) (Chen L et al., 2005). 
 
Cell cultures and cytotoxicity assay 
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A549 alveolar epithelial cells (1.2x105/ml) were seeded on chamber slides and incubated with 500 µl cell 
culture medium DMEM per well over night until they reached a cell number of 2.4x105/ml. P. aeruginosa 
strains were cultured overnight in 5ml Trypton Soy Broth (TSB). From the overnight culture a fresh culture 
in 5ml TSB (optical density, OD 0.05) was prepared and incubated at 37°C until a optical density of 0.5 (4-
5x108 CFU/ml) was reached. This culture was centrifuged (2700 x g) at 4°C for 15 min and the culture 
supernatant was harvested and filtered through a sterile filter (pore size 0.22 µm). From the culture 
supernatant 500 µl were put into the wells of a chamber slide containing A549 cell monolayer and 
incubated for 3h at 37°C 5% CO2. The bacterial cell pellet was resuspended in 10 ml cell culture medium 
DMEM without antibiotics, centrifuged (2700 x g) at 4°C for 15 min and resuspended in 1 ml DMEM. This 
bacterial suspension was diluted with DMEM to obtain a bacterial cell number of 2x105 CFU/ml. In order to 
block unspecific binding of the bacteria, bovine serum albumin (1%) in DMEM was put into the wells the of 
a chamber slide containin A549 cell monolayers and incubated for 30 min at 37°C 5% CO2. From the 
bacterial suspension 500 µl were put into the wells of the chamber slide and incubated for 3h at 37°C 5% 
CO2. After incubation of the culture supernatant and bacteria cells with the A549 cells the culture 
supernatant was removed and the cells were stained with 200 µl solution, containing 4 µl PI and 4 µl Syto 
13 and 2 ml phosphate buffered saline (PBS), for 10 min at 37°C in a dark chamber. The cells were washed 
three times with 500 µl PBS and fixed immediately with 5% glutaraldehyde (Sigma) over night at 4°C. The 
cells were washed, the chamber was removed and the slide was embedded in Fluorescence mounting 
medium (Dako). The cells were analysed with the Zeiss Axioplan Fluorescence Microscope and the Axio 
Vision Programm (Zeiss). Five digital pictures were taken from each well at a magnification of 200. Dead 
cells were calculated by counting the yellow cells (dead cells) resulting from co staining of PI and Syto 13 
compared to green cells (living cells) only stained with Syto 13. 
 
Cell culture and invasion assay 
The A549 (human type II pneumocytes) cell line was purchased from ATCC CCL-185 and cultured as 
described (Pirone et al., 2008). Bacteria invasion assay was performed using Polymvxins B (100 μg/ml) 
(Sigma) protection assay with minor modifications (Lorè et al., 2012). P. aeruginosa strains, grown to the 
mid-exponential phase, were used to infect cell monolayers at a 100:1 multiplicity of infection for two 
hours. The monolayers were washed with PBS, treated with antibiotic for two hours, washed, lysed with 
H20 and plated on TSB-agar plates (Difco). 
 
IL-8 secretion 
IL-8 was determined in supernatants collected from the cell cultures described above using an ELISA kit 
(Biosource Europe). According to the manufacturer the sensitivity of the assay is less than 0,7 pg/ml. Values 
were normalized to 106 cells; results were expressed as mean +/- SD. 
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Mouse model of acute P. aeruginosa infection  
C57Bl/6NCrlBR mice (20-22 gr) were purchased from Charles River Laboratories, Italy. Mice were housed in 
filtered cages under specific-pathogen conditions and permitted unlimited access to food and water. 
Prior to animal experiments, the P. aeruginosa mutant strains were grown for 3h to reach mid exponential 
growth phase. Next, bacteria were harvested, washed twice with sterile PBS and the OD of the bacterial 
suspension adjusted to an OD 600 nm. Planktonic bacteria were resuspended in sterile PBS to the desired 
dose for infection of 5x106 CFU/mouse. Mice were anesthetized and the trachea directly visualised by a 
ventral midline incision, exposed and intubated with a sterile, flexible 22-gr cannula attached to a 1 ml 
syringe accordingly to established procedures (Bragonzi et al., 2009). A 60 µl inoculum of 5x106 CFU were 
implanted via the cannula into the lung, with both lobes inoculated. After infection, survival was monitored 
twice a day for up to four days.  Mice that lost >20% body weight and had evidence of severe clinical 
disease, such as scruffy coat, inactivity, loss of appetite, poor ambulation, dehydration or painful posture, 
were sacrificed by CO2 administration before termination of the experiment. In another group of mice, the 
lungs were excised and processed for histopathology. 
 
Histological analysis 
Mice were sacrificed by CO2 administration after 24h of infection, lungs were removed en bloc and fixed in 
10% buffered formalin at 4°C for at least 24h and processed for paraffin embedding. Longitudinal sections 
of 5 μm from the proximal, medial and distal lung regions were obtained at regular intervals using a 
microtome. 
Sections were stained with haematoxylin and eosin according to standard procedures. Areas of 
inflammatory cell infiltration and tissue preservation (normal histology) were quantified using Image J 
software (National Institutes of Health) and reported as a percentage of total area. 
 
Statistical analysis 
Results are presented as mean ± SEM. Statistical calculations and tests were performed using Student’s 
paired t-test, and Log rank Mantel-Cox test in order to determine the significance of differences in means 
between pairs.  
 
Results  
Identification of P. aeruginosa transposon mutants with pleiotropic phenotypes  
To identify novel genes involved in the virulence of P. aeruginosa and which can be exploited as 
antimicrobial targets, a strategy involving a multistep sequential approach shown in Figure 1A was used.  
This started with the construction of a Tn5 mutant library in P. aeruginosa. To perform this mutagenesis 
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pLM1 was used due to the high transposition efficiency of this Tn5-based vector in P. aeruginosa (Larsen et 
al., 2002). We used PAO1-L as the strain of choice since we did not identify some of the alterations found in 
other PAO1 strains such a large genomic deletion from PAO1-N (Prochnow et al., in preparation). A total of 
57,360 mutant strains (598 plates of 96 individual mutants) were obtained by conjugation. We estimated 
that around 60,000 mutants of PAO1-L needed to be generated to have 95% chance of disrupting any given 
gene of 327 bps according to Liberati et al (2006). To enable the use of a high throughput (HTP) screening 
for the isolation of mutants with attenuated virulence, simple bioassays were designed using a robotic 
system (Fig. 1A). All the mutants were tested individually in qualitative manner for attenuations in 
swarming, the loss of the blue pigment pyocyanin in liquid media, and reduction in protease production 
using 5% skimmed milk agar plates. All mutants with alterations on one of these three phenotypes were 
then rescreened for attenuation of the other two phenotypes (Fig. 1A). A total of 404 mutant strains 
showing pleiotropic phenotypes (Fig. 1B) were selected for the second stage of screening using the C. 
elegans and D. melanogaster infection models. 
 
Impact of pleiotropic selected mutants on virulence attenuation using the C. elegans and D. 
melanogaster disease models 
The 404 mutants showing pleiotropic phenotypes from the initial Tn5 library screening were further tested 
in a second stage screening. This was based on the use of C. elegans and D. melanogaster as infection hosts 
to identify attenuated mutants.  The aim was to further shortlist these mutants prior to evaluating their 
cytotoxicity in eukaryotic cells lines (Fig. 1A and 1B).  
From a total of 404 transposon mutants tested, 108 were found to be attenuated in at least one of the 
infection models. All 108 mutants were further characterized using quantitative assays for alteration of 
swarming, pyocyanin and alkaline protease (as described in the supplementary materials and methods). In 
this characterization, we included also a total of six mutants (PA5156, PA4265, PA3613, PA3448, PA0534 
and PA0425) that were not attenuated either in C. elegans or in D. melanogaster as part of the validation of 
our screening strategy. It is important to note that none of the mutants showed growth defects (data not 
shown). This screening identified a total of 47 mutants attenuated in all three virulence traits, 51 mutants 
in two traits and 16 mutants in one trait.  The insertion sites of the 108 transposon mutants attenuated in 
C. elegans or D. melanogaster and the six “control” mutants not attenuated in these models were identified 
with a view to eliminate mutant redundancy (see materials and methods). These resulted in a reduction of 
the numbers of mutants with attenuated virulence in at least one non-mammalian model to 67 with unique 
insertions in ORFs, representing 1.3% of the entire genome coding sequence, plus 4 within intergenic 
regions, (Stover et al., 2000) (Fig. 1A and 1C). Table 1 shows the detailed results obtained for 71 mutants 
selected, including also 6 mutants without attenuation in non-mammalian models as described before.  
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Functional diversity of the genes involved in virulence   
Analysis of the predicted proteins encoded by the 67 ORFs with unique Tn5 insertions and attenuated in 
virulence revealed that these proteins are involved in various cellular functions (Table 1). These proteins 
were grouped into seventeen functional gene classes, including energy, amino acid and nucleotide 
metabolisms, transcriptional and post-transcriptional regulation, motility and adaptation, secretion and 
transport of small molecules, enzymes as well as conserved hypothetical proteins of unknown functions 
(Table 1). There was a wide spread distribution for the predicted functional category of the mutated genes, 
with the highest abundance corresponding to 24 genes with unknown function followed at a distance by 7 
genes involved in transport of small molecules. (Table 1 and Fig. 2). For all the genes identified only 20 had 
been previously demonstrated to be involved in virulence determinants in P. aeruginosa. The various 
functions of these 20 genes, including antibiotic resistance (parR, phoR, mexA and rpoS), biofilm formation 
(pelG, pslJ, mucP and cupA3), virulence factors delivery (tssA1, pilD, xcpT and plcH), regulation (pqsA, pqsC, 
pvdQ, crc, pilU and ptsP), and metabolism (bphO and nagE) (Table 1) support the robustness of the 
screening strategy used. In order to validate our screening method, we compared the 67 genes identified 
with two unbiased screens based on negative and positive signature tagged mutagenesis (STM) selection 
methods. The negative selection approach applied to animal models of short-term acute infection 
identified P. aeruginosa mutants with attenuated virulence, while the positive approach searched for P. 
aeruginosa pathogenicity-adaptive mutations in a murine chronic respiratory infection models (Potvin et 
al., 2003; Bianconi et al., 2011). Our screen identified six genes that were already selected by negative-STM 
selection (ORFs PA3110, PA4098, PA4489, tssA1, cupA3, pilD) and one by positive-STM selection (nqrB) 
(Potvin et al., 2003; Bianconi et al., 2011) (Table 1). 
We compared the results obtained in C. elegans in our work with the large set of virulence genes identified 
by Feinbaum and colleagues (Feinbaum et al., 2012) using the same non-mammal model. Our screen 
identified two genes selected also in Feinbaum work (ptsP, gshA) (Table 1). In particular, pstP was 
previously demonstrated to be a virulence factor in C. elegans (Tan MW et al., 1999) (Table 1). 
 
In silico and comparative genomic analysis of selected targets 
Among the 67 targets identified, with the exclusion of the intergenic regions, 18 belong to the class of 
confidence 1 and are fully characterized in P. aeruginosa, 14 belong to class 2 and are similar to protein 
characterized in other species, 12 belong to class 3 and 23 belong to class 4, these last targets have an 
hypothetical function or they are completely unknown. Among the targets, six (tssA1, pilU, plcH, pvdQ, 
mucP, pilD) are known virulence factors annotated in the VFDB (Virulence Factors Database). 
Pseudomonas aeruginosa isolates have a highly conserved core genome representing up to 90% of the total 
genomic sequence with additional variable accessory genes, many of which are found in genomic islands or 
islets. Exchange of loci encoding virulence genes may occur by mutations and homologous recombination 
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which occur frequently in P. aeruginosa particularly in CF patients. To address the global relevance of these 
virulence factors, a comparative protein sequence analysis was carried out against six sequenced genomes 
(PA14, LESB58, PA7, 2192, C3719 and PACS2) of P. aeruginosa and against E. coli K12 and B. cenocepacia 
J2315 in order to check presence and conservation of our candidates in other P. aeruginosa genomes and in 
other bacterial species (Table 2S). The majority of the selected targets are conserved in all the six P. 
aeruginosa genomes analysed, eight are conserved in five genomes, one (tufA) is conserved only in four 
genomes and one (PA0823) only in three genomes. Ten targets are highly conserved in B. cenocepacia 
J2315, with a homology higher than 60%, whereas 22 have no or very poor (<20%) homology. tufA has a 
very high homology (>80%) with E. coli K12, 26 targets are rather conserved with a homology between 41% 
and 60%, while the majority of the targets (35) are poorly conserved, with a homology between 20% and 
40%. 
Nine targets (tssA1, ptsP, cupA3, nqrB, pilD, gshA, the ORFs PA3110, PA4098, PA4489) were previously 
identified in other in vivo large genomic screenings as factors strictly related to P. aeruginosa virulence, as 
hinted in the previous paragraph (Bianconi et al., 2011; Potvin et al., 2003; Winstanley et al., 2009; 
Feinbaum et al., 2012).  
Complete homology analysis of the selected targets is present in table S2 (supplementary material). 
 
Validation of targets selected for murine acute infection 
For the next stage in the evaluation of the strategy outlined in this manuscript for the identification of 
virulence targets, eight mutant strains attenuated in one, both or none of the C. elegans and D. 
melanogaster disease models were selected for further validation analysis using: (i) quantitative in vitro 
analysis for attenuation of virulence traits, (ii) C. elegans and D. melanogaster killing curves, (iii) cell 
invasion and (iv) cytokine production assays.  The selected mutants were pvdQ and crc as they were 
attenuated in all phenotypes, disease models and cytotoxicity assays (Table 1), the mutants in kdpB, bphO, 
PA2414 and PA4916 as they were attenuated in one of the disease models and showed differences in vitro 
virulence assays, and finally PA5156 and PA3613 as they did not show attenuation in the disease models 
but showed again different levels of attenuation in the other virulence assays (Table 1).  
Analysis of the 8 selected mutants for surface motility, biofilm formation, and their ability to produce 
elastase and pyoverdine showed in all of them a reduction in the production of elastase and biofilm 
formation. However PA3613 did not show any reduction in pyoverdine, or any of the motility tests used as 
anticipated from the results shown in (Fig. 1S).  
The impact of the 8 selected mutations on D. melanogaster and C. elegans was confirmed by following 
hosts survival rate over a period of 24h for C. elegans and 72h for D. melanogaster (Fig. 3).  
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The killing curves confirmed the results shown in Table 1, except that PA1634 was found to be more 
pathogenic for C. elegans than in the initial screen (Fig. 3A). Notably, the crc mutant was the most 
attenuated strain in both infection models (Fig. 3). 
In accordance with the previous outcomes of the sequential screening cascade approach we challenged 
A549 cells with the eight mutants in order to validate the attenuation of the candidates in terms of invasion 
capacity and secretion of the pro-inflammatory cytokine IL-8 (Fig. 4). Seven out of the eight mutants 
selected were significantly attenuated in term of invasion capacity (PAO1-L wild type vs kdpB p<0.001 pvdQ 
p<0.001, bphO p<0.001, crc p<0.001, PA2414 p<0.05, PA4916 p<0.01, PA5156 p<0.001 ) and six mutants 
were attenuated in IL-8 release (PAO1-L wild type vs kdpB p<0.05, pvdQ p<0.05, bphO p<0.01, PA5332 (crc) 
p<0.05, PA2414 p<0.05, PA5156 p<0.01, and) in comparison to the wild type PAO1-L (Fig. 4A and B).  
 
Impact of selected mutants in the mouse model of acute lung infection  
Combining all the results from in vitro screening and virulence assays, 8 Tn5 mutants (kdpB, pvdQ, bphO, 
crc, PA2414, PA3613, PA4916, PA5156) were selected in order to test differences in lethality in the 
mammalian host using a murine model of acute lung infection (Fig. 5). First, escalating doses ranging from 
5x105 to 107 CFU of wild type PAO1-L were intratracheally injected in C57BL/6NCrlBR mice to determine the 
relative range of susceptibility (Fig. 2S). The first lethal dose was 5x106 CFU/lung (Fig. 2S). C57BL/6NCrlBR 
mice were then infected by intra-tracheal injection with 5x106 CFU of planktonic wild type PAO1-L and 
transposon mutants and survival monitored up to 96h (Fig. 5). While wild type PAO1-L was totally lethal 
within 36h, the lethality of transposon mutants was significantly lower and temporally shifted (Fig. 5A). Five 
of these mutants were significantly attenuated in inducing mortality when compared to wild type PAO1-L 
(wild type PAO1-L vs pvdQ, bphO, crc p<0.001; wild type PAO1-L vs PA4916 and PA5156 p<0.05; Mantel-Cox 
test) (Fig. 5A). Among these mutants attenuated, it should be noticed that both PA4916 and PA5156 were 
not attenuated in C. elegans and in other models. In addition, mutants attenuated in C. elegans were not 
attenuated in the mouse model. Overall, these results suggest a host-specific response to P. aeruginosa and 
indicate the necessity to test a selection of mutants in the mouse model, as the nearest to the human host. 
Furthermore, histopathological analysis (Fig. 5B) showed that wild type PAO1-L strain (Fig. 5C) induced 
slightly highest inflammation and haemorrhage in comparison to the crc (Fig. 5D) and pvdQ mutants (Fig. 
5E). The area infiltrated by inflammatory cells was significantly higher in the lungs infected by wild type 
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In this study, we have described a new screening strategy combining an in vitro testing for reduced 
production of virulence factors and validation in a cascade of in vitro and in vivo virulence models including 
airways cells, C. elegans, D. melanogaster and a mouse model of acute lung infection. We have isolated a 
total of 404 independent pleiotropic mutants (attenuated in two or more virulence traits). All 404 mutants 
were screened for reduced virulence in the two non-mammalian infection models. Mutants that showed 
reduced virulence in at least one of these models were tested for their reduced cytotoxicity on A549 
alveolar epithelial cells. Consequently, a total of 114 mutants were selected for identification of the 
inserted gene, leading to the identification of 67 virulence genes. Through our screening, we were able to 
isolate a large number of mutants with insertions in genes already demonstrated to be required for P. 
aeruginosa virulence in nematodes and mammals, including genes involved in antibiotic resistance, biofilm 
formation, virulence factors production, metabolism and quorum sensing regulation. Bioinformatics was 
employed to select targets broadly conserved among the desired bacterial spectrum, but absent or 
evolutionary distant in eukaryotes. A large proportion of the identified genes were highly conserved within 
P. aeruginosa and the two Gram negative pathogens E. coli and B. cenocepacia. Six of the 67 identified 
genes are in the database of Pseudomonas related virulence (VFDB) and 9 genes were previously identified 
as related to P. aeruginosa virulence (Bianconi et al., 2011; Potvin et al., 2003; Winstanley et al., 2009; 
Feinbaum et al., 2012).  
A comparison with the recently published C. elegans screen from Feinbaum et al. (2012) showed that there 
is little overlap between the two screening strategies. Both screens have identified orfs from gshA-B and 
kpdB-D operons. In their paper, Feinbaum and colleagues hypothesised that kdpD and gshA-B could be 
required for Pseudomonas adaptation in the host since the loss of membrane integrity of a kdpD mutant 
and the susceptibility of a gshA mutant to pH variation may affect bacterial cell survival (Feinbaum et al., 
2012). Similar to the C. elegans screen, we identified a number of genes that are involved in adaptation to 
environmental stress by playing a protective role. Those include a large number of metabolic genes 
involved in the generation and transport of precursor metabolites and energy (fdhE, ptsP, xdhB, bphO, 
nqrB, nagE and PA2414), and genes involved in DNA synthesis and modification (smpB, pdxA, PA3867, 
PA3950 and PA4282) (Table 1 and Fig. 3). Interestingly, genes playing a part in amino acid synthesis and 
metabolism were identified (pauB1 coding for a D-amino acid oxidase, hisD coding for a histidinol 
dehydrogenase, PA3139 coding for a threonine-phosphate-decarboxylase). Amino acids are available to 
bacterium in the lung environment and a more efficient amino acid acquisition could be related to the 
biosynthetic cost of producing each metabolite. The identification of a number of mutants corresponding to 
biofilm formation (psl, mucP and pelG), type IV and VI secretion systems (xcpT, pilD and tssA1), and stress 
response (phoR, rpoS and parR) also illustrate their importance for survival of P. aeruginosa in the “host 
environment”. With respect to the virulence screening assays, one explanation for why a majority of the 
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mutants identified in this study correspond to metabolic and stress adaptation functions may be the 
growth conditions (e.g. low aeration) applied during the screening. 
Our screening approach favoured the identification of mutants attenuated in all virulence factors. However, 
the observation that six mutants (PA5156, PA4265, PA3613, PA3448, PA0534 and PA0425) were selected 
for their pleiotropic phenotypes but were not attenuated in the disease models C. elegans and D. 
melanogaster demonstrates the importance of the simultaneous utilization of multiple screening 
strategies.  In addition, while we have found accordance between presence or absence of attenuation for 
some targets in C. elegans and in the murine model (kdpB, pvdQ,  bphO, crc, PA3613), PA2414 was 
attenuated in C. elegans but not in mice and PA4916 and PA5156 were attenuated in the mouse model of 
acute infection, but not in C. elegans. Other incongruities were observed between the results obtained in 
mice and those from other screenings. Our data show that identification of virulence genes carried out 
mainly in vitro does not imply that they are relevant for their pathogenesis in vivo. In the context of 
infections caused by P. aeruginosa virulence is mediated by a wide variety of trans-acting regulators that 
sense the environment and the physiological state of the cell and adjust the transcription of specific genes 
changing their phenotype significantly. The use of non-mammalian infection models has several downsides, 
as the temperature for the cultivation of the nematode that affects the expression of certain virulence 
factors, the absence of the target organ and the lack of specific receptors or pathways. However, although 
rodents are the first choice for understanding infectious diseases in human, screening a large amount of 
targets in mouse models is unfeasible. Despite the downsides described above, non-mammalian models 
remain useful surrogate hosts. In addition to being largely used to identify virulence factors, C. elegans has 
been exploited to study responses to infection as well as to compare the virulence of clinical and 
environmental isolates (Monk et al., 2008). Furthermore, pathways conserved in vertebrates characterize 
Drosophila response to pathogens, and mammalian and C. elegans innate immune defenses (Ferrandon et 
al., 2007;. Engelmann et al., 2010). Therefore, a multifaceted bottleneck approach, by using a sequential 
cascade of models to provide the rationale and the proof-of-concept, is essential for the characterization 
and validation of a large number of bacterial target candidates. However, the approach employed in this 
work, although representing a step forward in understanding P. aeruginosa pathogenesis, does not totally 
reflect the complex situation taking place in infected patients. Several evidences are transforming the view 
of infectious diseases from strictly pathogen-centric to the one incorporating host environmental and 
genetic determinants that modulate immune response. Thus, a wide combination of different validation 
models including mouse model, as the nearest to the human host, are necessary to test mutant strains of P. 
aeruginosa, although not thoroughly exhaustive. 
The selection of virulence mutants based on pyocyanin deficiency could be another limitation to the 
screening strategy. It is still controversial whether this phenazine correlates with worse conditions in CF 
patients (Carlsson et al., 2011; Hunter et al., 2012; Rada et al., 2013).  In addition, Bianconi and colleagues 
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(Bianconi et al., 2011) have found that a PilY1 mutation favors P. aeruginosa persistence. The absence of 
PilY1 leads to a reduction of pyocyanin, which suggests that inhibiting pyocyanin synthesis could favor 
bacterial persistence thus leading to chronic infections in CF. 
Growing knowledge about the physiology of pathogens and hosts over the last decade has boosted the 
molecular understanding of the factors that promote bacterial pathogenicity in the course of the infection 
process. Anti-virulence signalling strategies (Rasko et al., 2010; Brotz-Oesterhelt et al., 2010; Fernebro, 
2011) may specifically interfere with the ability of the bacteria to recognize host signals and/or activate 
specific virulence traits that are needed to establish infection. By preventing the expression or activity of 
virulence traits, the bacteria are less able to colonize the host. Broad-spectrum antibiotics are not always 
the best choice, especially not when considering the commensal flora and the risk for opportunistic 
infections. The removal of species, or alteration of the balance of species in a community as complex as the 
gastrointestinal or airways microbiota, could result in detrimental effects for the host. Targeting bacterial 
virulence is attractive since it is specific toward pathogenic bacteria and spares the commensal flora. In 
addition, as this strategy does not directly kill the bacteria, there is presumably less evolutionary pressure 
for the development of resistance than with traditional antibiotics. This inhibition could also allow the host 
immune system, including the normal microbiota, to prevent bacterial colonization or clear any established 
infection. Some concerns should be considered about anti-virulence therapy for P. aeruginosa infections. P. 
aeruginosa virulence is a highly complex, multifactorial process requiring the coordinated activity of many 
bacterial gene products which can be widely different depending on the infection is established. The idea of 
a core set of virulence factors common to all infection models is unlikely. The spectrum of virulence factors 
that play a role in a given host model depends on a wide variety of factors including the characteristics of 
the site of infection, the type of the immune response and the phase of infection, and even host behavior. 
Virulence factors playing a role in distinct types of P. aeruginosa infection in humans could be different, 
implicating a great effort to personalize the treatment and thus posing a challenge for the development of 
new therapeutics.  
Another concern deals with the anti-virulence approach in CF chronic infection. It has been shown that 
long-term colonization of the CF host is maintained by P. aeruginosa patho-adaptive lineages, which are 
clonal with the initially acquired strain and carried phenotypic variants (Smith et al., 2006). A number of 
genetic mechanisms are responsible for generating clonal variants in P. aeruginosa. Most CF strains 
consistently acquire common mutations in virulence genes including in motility genes, in quorum-sensing 
regulator, in the type-III secretion system, in the multidrug-efflux pump and in mutator phenotypes 
(Bragonzi et al., 2009; Alcalá-Franco et al., 2012). Interestingly, virulence factors required for the initiation 
of acute infections were selected against during chronic infection. This indicates reduced virulence of the 
late strains with regard to their ability to provoke acute infection. This evolutionary scenario is similar to 
that of the genomes of other pathogens. Genetic loss-of-function mutations confer indeed enhanced 
                                                            Dissection of the role of P. aerugniosa and host factors 
 110 
fitness of the pathogen in a host-associated environment as shown for other pathogen (Akopyants et al., 
1995; Moxon et al., 1978; Sokurenko et al., 1998). Loss of virulence factors thus represents a strategy used 
by the pathogen to adapt to the environment and persist in the host (Bianconi et al., 2011). This raises the 
question whether anti-virulence therapy could favor P. aeruginosa fitness to the CF lung leading to chronic 
infections. One possibility could be to target virulence genes only during acute phases of P. aeruginosa 
infection in CF patients, aiming to the eradication by the host immune system. 
Anti-virulence strategies have still been poorly exploited to treat P. aeruginosa infection and they were 
directed mainly towards known virulence targets, namely PcrV, a protein of the T3SS, and the O-
polysaccharide moiety of P. aeruginosa serotype O11 (Baer et al., 2009; Lazar et al., 2009). This could be 
due to the fact that large parts of P. aeruginosa genome, in which an array of unknown antimicrobial 
targets may be hidden, are still unexplored, probably for the lack of genetic and functional tools for large-
scale screening.  In this study, out of 67 genes, our multifaceted screening approach identified 22 new 
virulence genes with still unknown function, 3 of which (PA2414, PA4916 and PA5156) were validated in 
murine model of acute infection. We identified a large number of unstudied genes that are involved in 
virulence and that might turn out to be targets of clinical relevance. Furthermore, the observation of 
independent selection of multiple strains with the same mutation indicated that our screen was effective in 
determining virulence deficiencies.  
In summary, by using a genomic approach devised to screen the entire P. aeruginosa genome for novel 
virulence genes and a multifaceted approach based on a sequential cascade of models for the validation 
step, we have identified several novel virulence genes. These genes should be further investigated for their 
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Table 1. List of the genes involved in P. aeruginosa PAO1-L virulence. The attenuated phenotype is 
indicated by a red box while not attenuated phenotype is indicated by a blue box. Genes are ordered 
according to their increasing locus tag-PA number in PAO1. The number of transposon insertions, the class 
of confidence (1: function experimentally demonstrated, 2: function of highly similar gene experimentally 
demonstrated in other organism, 3: function proposed based on presence of structural feature, 4: homolog 
of previously reported genes of unknown function), if targets are annotated as known virulence factors, the 
homology with other than PAO1 P. aeruginosa genomes and genome of other gram-negative species and 
the identification of the gene in other screening are also indicated. The eight genes which were examined 
for their involvement in pathogenesis using the murine acute infection model are highlighted in grey. & 
genes annotated as virulence genes in the Virulence Factor Database (http://www.mgc.ac.cn/VFs/); * 
numbers indicate the numbers of checked P. aeruginosa genome in which the target is conserved, 
homology >80%; # UH unknown homology, 0 homology <20%, 1 homology between 20-40%, 2 homology 
between 41-60%, 3 homology between 61-80%, 4 homology >80%; ~ Infection assays were carried out as 
described in the Material and Methods. Mutant strains were considered to be attenuated when more than 
40% of the flies survived 24 h post infection; $ Bacteria were grown for 3 h and washed bacteria were 
incubated with A549 cells.  Culture supernatants were obtained from bacteria grown for 18 h and 
incubated with A549 cells. Cytotoxicity lower than 4% was defined as highly decreased cytotoxic capacity. 
Three independent experiments were performed with triplicates. Values represent mean ± standard 
deviation (SD). The Student’s t-test was used. 
Figure 1. Selection of P. aeruginosa transposon mutants with pleiotropic phenotype. A) Screening 
strategy leading to target identification. A transposon library of P. aeruginosa PAO1-L comprising 57,360 
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mutants were screened for attenuated virulence in vitro, including production of protease and pyocyanin 
and swarming motility. A total of 404 transposon mutants having a pleiotropic phenotype were further 
tested in a sequential cascade of disease models including A549 epithelial cell line, C. elegans and D. 
melanogaster, resulting in the selection of 114 to be mapped. A total of 8 mutants which were attenuated 
in both, one or none of the disease models were evaluated in a mouse model of acute infection to provide 
rational and proof of concept. B) Summary of the results of the in vitro screening. A total of 404 mutants 
having pleiotropic phenotypes (impaired in protease, pyocyanin and swarming motility) were further 
examined in vivo. C) Summary of the results of the transposon library.  
 
Figure 2. Proportion of genes (sorted by function) represented in the list of 67 candidate targets. 
 
Figure 3. Virulence of P. aeruginosa PAO1-L and investigated transposon mutants in C. elegans and D. 
melanogaster disease models. A) Lethality curves in D. melanogaster disease model. B) Lethality curves for 
8 investigated mutants in the C. elegans disease model. The results presented here show the mean values 
and standard errors calculated from three independent experiments.       
 
Figure 4. Virulence of P. aeruginosa PAO1-L and its transposon mutants in A549 alveolar cells. A total of 8 
transposon mutants of P. aeruginosa PAO1-L were screened for their ability to invade the bronco-epithelial 
cell line A549 and to induce IL-8 release. A) Internalization of the bacterial cells was tested using an 
antibiotic exclusion assay. A total of seven mutants out of eight (kdpB, pvdQ, bphO, crc, PA2414, PA4916, 
PA5156) were significantly attenuated in their capacity to invade A459 in comparison to wild type strain. B) 
IL-8 release was measured by ELISA in the supernatant of cells infected with the transposon mutants. IL-8 
release was significantly attenuated in the supernatants of A549 cells after infection with six transposon 
mutants (kdpB, pvdQ, bphO, crc, PA2414,  PA5156) in comparison to wild type PAO1-L. Data, from three 
independent experiments performed in triplicates, are expressed as mean +/- SD. *p<0.05, **p<0.01, 
***p<0.001 in the Student’s t-test.   
 
Figure 5. Virulence of P. aeruginosa PAO1-L and a selection of transposon mutants in a mouse model of 
acute lung infection in C57BI/6NCrI mice. Mice were intratracheally injected with 5x106 CFU of PAO1-L wild 
type or Tn5 mutants. A) Survival was monitored up to 96 hours. Five of these mutants were attenuated in 
inducing mortality when compared to the wild type, bphO, pvdQ, crc, PA4916 and PA5156. B) Lung 
histopathology was performed after 24h from infection for wild type PAO1-L , pvdQ , and crc. Infiltrated 
area was evaluated based on histopathology. C) Evaluation of the inflammatory score showed that crc and 
pvdQ were slightly attenuated in their capacity to induce leukocytes recruitment and lung damage in 
comparison to the wild type. Two independent experiments were pooled. Statistical analysis was calculated 
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for pair wise comparisons between wild type and mutant strains. *p<0.05, **p<0.01, ***p<0.001, Mantel-
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Figure 4 
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Figure 5 
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Table 1. List of the genes involved in P. aeruginosa PAO1-L virulence. The attenuated phenotype 


















































































































































































































PA0082 tssA1 2 2 yes               6 1 1 





PA0337 ptsP 1 1                 6 1 2 





PA0366   1 3                 6 2 1   
PA0396 pilU 1 1 yes               6 1 1   
PA0425 mexA 1 1                 6 3 2   
PA0534 pauB1 1 2                 6 3 1   
PA0593 pdxA 1 2                 6 2 3   
PA0823   1 4                 3 1 1   
PA0844 plcH 1 1 yes               6 2 1   
PA0914   1 4                 5 0 2   
PA0996 pqsA 1 1                 6 1 1   
PA0998 pqsC 1 1                 6 1 2   
PA1030-P8 P8 2 4-1                         
PA1118   1 4                 6 0 2   
PA1523 xdhB 1 2                 6 2 1   
PA1542   1 4                 6 2 1   
PA1634 kdpB 7 2                 6 2 3   
PA1799 parR 2 1                 6 2 2   





PA2240 pslJ 1 1                 6 0 1   
PA2385 pvdQ 2 1 yes               6 0 1   
PA2414   1 2                 6 1 2   
PA2781   1 4                 6 1 1   
PA2854   2 4                 6 UH 1   
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PA2998 nqrB 1 2                 6 0 1 









PA3058 pelG 1 1                 6 0 1   
PA3071   1 4                 6 1 1   
PA3101 xcpT 3 1                 6 2 2   
PA3110   1 4                 5 UH 1 





PA3139   1 3                 6 3 2   
PA3257 prc 1 2                 6 1 1   
PA3270   1 4                 6 1 1   
PA3327   1 3                 5 1 1   
PA3448   1 3                 6 3 2   
PA3449   1 4                 6 3 1   
PA3460    3 3                 6 0 2   
PA3493   1 4                 6 0 2   
PA3613   1 4                 6 0 2   
PA3622 rpoS 11 1                 5 2 3   
PA3649 mucP 3 1 yes               6 2 2   
PA3761 nagE 1 1                 6 2 2   
PA3799   7 4                 6 2 2   
PA3867   2 3                 6 0 1   
PA3950   1 3                 3 3 2   
PA4000   1 4                 6 0 1   
PA4059   1 4                 6 UH 3   





PA4113   1 3                 6 1 2   
PA4116 bphO 1 1                 6 UH 2   
PA4265  tufA 1 2                 4 4 4   
PA4282 sbcC 2 3                 6 0 1   
PA4352   2 4                 6 UH 1   
PA4448 hisD 1 2                 6 3 2   
PA4489   1 4                 6 UH 2 





PA4498   1 3                 6 1 1   
PA4515   3 4                 6 2 2   
PA4528 PilD 1 1 yes               6 2 2 





PA4684   1 4                 6 0 1   
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PA4767-68   2 4-2                         
PA4768 smpB 1 2                 6 2 2   
PA4809 fdhE 1 2                 6 1 1   
PA4916   1 4                 6 0 1   
PA5022   1 4                 6 0 1   
PA5138   1 4                 6 0 2   
PA5156   1 4                 6 1 1   
PA5202-03   1 4-2                         
PA5203 gshA 4 2                 6 2 2 





PA5332 crc 1 1                 6 1 1   
PA5360-61 phoB-phoR 1 1-2                         
PA5361 phoR 1 2                 6 2 1   
PA5548   1 3                 5 1 1   
 
& Present in the Virulence Factor Database (http://www.mgc.ac.cn/VFs/) 
* Number of genome in which the target is conserved, homology >80% 
# UH uncertain homology 
   0 homology <20% 
   1 homology between 20-40% 
   2 homology between 41-60% 
   3 homology between 61-80% 
   4 homology >80% 
~ Infection assays were carried out as described in the Material and Methods. Mutant strains were considered as attenuated when 
more than 40% of the flies survived 24h post infection 





Supplementary material and method 
Pyocyanin and pyoverdine production 
In order to test pyocyanin production, P. aeruginosa strains were grown at 37oC in LB for 16h. The 
concentrations of pyocyanin were determined in 5 ml culture supernatants as described previously (Essar 
et al., 1990). For pyoverdine production, P. aeruginosa cells were grown in CAA medium for 24h (Ongena et 
al., 2002). Pyoverdine production was assessed by determination of the optical density of culture 
supernatants at 400 nm.   
 
Protease and elastase activity 
Protease and elastase activities were assessed by using a colorimetric method (Ohman et al., 1980). Briefly, 
overnight cultures of 100 µl were added to a buffer containing 100 mM Tris, 1 mM CaCl2 (pH 7.5) and 5 mg. 
ml-1 of the substrates azocasein (Sigma) for protease detection assay or elastin congo red (Sigma) for 
elastase detection assay. The enzymatic reactions mixture were incubated at 37oC, and stopped after 15 
min using 500 μl of trichloroacetic acid 10% (v/v) for protease and after 2 h using 100 μl of 120 mM EDTA 
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for elastase. The level of enzymatic activity was determined by reading the optical density of clear 




Twitching assay was done using Difco LB broth solidified with 1% (w/v) Difco agar. Twitch plates were 
briefly dried and strains were stab inoculated with a sharp toothpick to the bottom of the Petri dish from an 
overnight-grown LB agar (1.5%, w/v) plate. After incubation at 37°C for 24 h, the zone of motility at the 
agar/Petri dish interface was measured.  
Swarming 
For swarming motility assay, a volume of 5 µl of an overnight (16 h) bacterial culture was spotted on 
swarming agar plate containing 5 g. l-1 Bacto agar (Difco), 8 g. l-1 Nutrient broth No2 (Oxoid), and 0.5% (w/v) 
glucose (Sigma), and incubated at 37oC for 16 h. 
Swimming 
Media used for swimming assay was Nutrient broth No2 (Oxoid), 0.5% (w/v) glucose (Sigma) and 0.3% (w/v) 
agarose (GIBCO/BRL). Swim plates were inoculated with bacteria from an overnight culture in LB agar 
(1.5%, 
w/v) plates at 37°C with a sterile toothpick. The plates were then sealed with parafilm (3M)  to prevent 
dehydration and incubated at 25°C for 12h. 
 
Biofilm formation 
The ability of P. aeruginosa PAO1-L to form biofilm was analysed using a bioflux system (Fluxion). Biofilm 
was grown continuously in microfluidic channels. P. aeruginosa PAO1-L wild type and its transposon 
mutants derivatives tagged with Tn7-egfp were grown at 37oC for 16h in 2 ml Müller Hinton (MH) (Oxoid) 
broth. The culture was refreshed, grown for a further 4h before setting up the biofilm experiment, and 
diluted to OD  0.05 in 7% MH broth. The biofilm was allowed to form in 10% MH broth at a flow rate of 
63μl/h (corresponding to a share rate of 2 dyn/cm2) at a temperature of 37oC for 15h. The microfluidic 
channel was assayed under a Laser Scanning fluorescent Microscope (LSM2, Zeiss). Biofilm was visualised 
using light microscope and egfp mode at an excitation wavelength of 488nm. Imaging was carried out using 
Zen 2009 imaging software (Zeiss). A number of 5 replicate images were taken randomly along the 
microfluidic channel with a Z-stack of 75 images. Biofilm images were analysed for biomass using Comstat 2 
statistical software (Heydorn et al., 2000). An automatic thresholding was applied using Ortsus’s method.   
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Supplementary figures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
Figure 1S. Phenotypic characterisation of P. aeruginosa PAO1-L and its transposon mutants PA1634 
(kdpB), PA2414, PA2385 (pvdQ), PA3613, PA4116 (bphO), PA4916, PA5156, PA5332 (crc). A) Protease, 
elastase, pyocyanin and pyoverdine production was determined in supernatant from culture grown to 
stationary phase using colorimetric assays. For twitching motility cells were inoculated with a toothpick 
from a LB agar plate onto a twitching plate (tryptone broth plus 1% agar). The diameter of the twitching 
zone was determined. Values of triplicate cultures are given. B) Biofilm formation was assessed using a 
bioflux microfluidic channel. Biofilm cells were continuously grown in 10% LB at 37oC for a period of 14h. 
Standard deviations are based on the mean values of six images taken in random locations in the 
microfluidic channel. C) For swarming and swimming motility, cell wer inoculated from a 16h LB culture 
onto swarming or swimming plates containing 0.5% or 0.3% agar, respectively. 
Figure 2S: Survival percent at different infection doses of wild type PAO1-L in C57Bl/6NCrl. C57Bl/6NCrl 
mice were intratracheally infected with escalating doses of wild type PAO1-L ranging from 5x105 to 107 CFU. 
Survival of infected mice was followed over a period of 4 days and is indicated as percent. The first lethal 















TABLE 1S. Bacterial strains and plasmids used in this study. 
Strain or plasmid Relevant characteristics Source or reference 
Strains   
Pseudomonas   
PAO1-L PAO1 Lausanne wild type Lausanne collection 
Escherichia coli   
λpir S17.1 Thi proA hsdR recA RP4-2-tet::Mu-1 kan::Tn7integrant (Tpr Smr) Metcalf et al. (1994) 
Plasmids   
pRL27 Plasmid harbouring Tn5 transposon, Kmr Larsen et al. (2002) 
pLM1 Plasmid harbouring Tn5 transposon derived from pRL27, Gent
r
 Larsen et al. (2002) 
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TABLE 2S. Percentage of homology of the amino acid sequence of the selected targets respect to P. 
aeruginosa strains LESB58, PA14, PA7, 2192, C3719 and  
Locus tag gene name 















      
 
PACS2 
       
 
Bcc J2315 
      
 
 Ec K12 
 Human 
homologs 
PA0082 tssA1 98 98 90 99 98 97 27 29.7 0 
PA0337 ptsP 100 100 99 100 100 100 35 42 0 
PA0366 
 
100 99 98 100 100 100 51 29 0 
PA0396 pilU 100 99 99 99 100 100 33 37 0 
PA0425 mexA 100 100 99 100 99 100 70 55 0 
PA0534 
 
100 99 96 100 99 99 67 40 0 
PA0593 pdxA 99 99 95 99 99 99 54 63 0 
PA0823 
 
98 98 30 37 32 98 31 34 0 
PA0844 plcH 99 99 96 99 99 99 42 32 0 
PA0914 
 
99 99 78 99 99 98 UH 44 0 
PA0996 pqsA 100 99 86 100 100 100 29 28.3 17 
PA0998 pqsC 100 100 97 100 100 100 27 50 0 
PA1030/P8 P8 
         
PA1118 
 
99 97 86 98 100 98 0 41 0 
PA1523 xdhB 99 99 98 99 99 99 55 25 2 
PA1542 
 
100 100 95 100 100 100 44 27 0 
PA1634 kdpB 99 99 98 99 100 99 60 60.6 23 
PA1799 parR 100 99 94 100 100 100 50 42 0 
PA2130 cupA3 99 99 69 99 98 99 27 31 0 
PA2240 pslJ 100 100 99 100 100 100 UH 26 0 
PA2385 pvdQ 99 99 94 99 99 99 UH 32 0 
PA2414 
 
99 99 94 99 99 99 25 41.4 0 
PA2781 
 
99 99 97 92 99 99 29 39 0 
PA2854 
 
100 100 98 100 100 100 UH 40 0 
PA2873 
 
99 99 88 98 98 98 UH 48.7 0 
PA2944 cobN 100 99 96 99 UH 99 57 23 0 
PA2998 nqrB 100 100 99 100 100 100 UH 29.1 0 
PA3058 pelG 100 99 96 100 100 99 UH 29 0 
PA3071 
 
100 99 96 100 100 100 32 38 0 
PA3101 xcpT 99 98 99 99 99 99 63 55 0 
PA3110 
 
99 96 94 64 99 100 UH 26.1 0 
PA3139 
 
100 99 97 100 100 100 73 52 3 
PA3257 prc 100 100 99 100 100 100 31 36 0 
PA3270 
 
99 100 95 100 100 100 37 30 0 
PA3327 NRPS 99 99 34 99 99 99 32 35 0 
PA3445 
 
100 99 99 100 99 100 65 48 0 
PA3448 
 
99 99 98 100 100 100 66 43.1 0 
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PACS2 and respect to B. cenocepacia J2315, E. coli K12 and humans. 




99 99 97 99 99 99 63 31 0 
PA3460 
 
100 100 98 100 99 100 UH 44 0 
PA3493 
 
100 100 86 100 94 100 0 46 0 
PA3613 
 
99 99 97 100 100 100 0 43 0 
PA3622 rpoS 100 100 99 100 UH 100 46 76 0 
PA3649 mucP 99 99 97 99 100 99 41 46 0 
PA3761 nagE 99 99 94 99 99 99 55 47 0 
PA3799 
 
99 99 100 100 100 100 55 59 1 
PA3867 
 
39 98 96 97 40 36 UH 36 0 
PA3950 
 
100 99 95 94 99 99 70 51 42 
PA4000 
 
99 99 97 99 89 99 UH 38.7 0 
PA4059 
 
99 98 96 98 97 98 UH 62 1 
PA4098 
 
100 100 96 99 100 100 63 34 0 
PA4113 
 
99 99 95 99 99 99 31 58 0 
PA4116 bphO 99 99 85 98 100 100 UH 42 0 
PA4130 
 
99 99 97 99 99 99 66 32.2 0 
PA4265 tufA 100 100 100 31 31 100 82 84 17 
PA4282 shsC 99 98 81 98 99 99 UH 28 0 
PA4352 usp 100 100 98 100 100 100 UH 22 0 
PA4448 hisD 100 100 98 100 99 100 69 41 0 
PA4489 
 
99 99 98 99 99 99 UH 53.3 1 
PA4498 
 
99 99 90 86 99 99 33 34 0 
PA4515 piuC 99 99 96 99 99 99 58 49 0 
PA4528 PilD 99 98 95 99 99 99 49 41.2 0 
PA4684 
 
99 100 99 99 99 100 UH 36 0 
PA4767-68 
          
PA4768 smpB 100 100 100 100 100 100 58 59 0 
PA4803 
 
100 100 33 100 100 100 UH 24.3 1 
PA4809 fdhE 99 99 98 99 99 99 38 39 0 
PA4916 
 
99 100 98 99 99 99 0 31 0 
PA5022 aefA 100 99 96 99 100 99 0 39 0 
PA5132 
 
98 98 96 98 92 99 38 27 0 
PA5138 
 
100 100 98 100 100 100 0 56 0 
PA5156 
 
99 99 94 99 98 99 26 37 0 
PA5202-03 
          
PA5203 gshA 99 99 96 99 99 99 53 42 0 
PA5332 crc 100 100 99 100 100 100 40 32.6 1 
PA5360-61 phoB-phoR 
         
PA5361 phoR 99 99 99 99 100 100 41 40 0 
PA5548 
 
99 98 28 99 99 98 31 23 0 
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